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Thesis  Summary 
 
 
 
In this thesis, I have described the work carried out on a single protein called 
RHAU, dealing with aspects of protein localization in cells, the regulation of 
global gene expression by different mechanisms, and cellular stress-responses. 
RHAU, RNA helicase associated with AU-rich element, was originally identified 
from the results of RNA affinity chromatography using the AU-rich element of 
uPA messenger RNA. RHAU was characterized as a factor accelerating AU-rich 
element-mediated mRNA degradation.  
 
The aim of this present study was to investigate possible role(s) of RHAU in 
mammalian cells. In the first part of the study, dealing with the cellular 
localization of RHAU using biochemical fractionation and microscopic analysis, I 
found that RHAU is predominantly localized in the nucleus, despite the fact that 
mRNA degradation occurs in the cytoplasm. In HeLa cells, RHAU is localized 
throughout the nucleoplasm with some concentration in nuclear speckles in a 
manner dependent on ATPase activity. Furthermore, it has been shown that 
transcriptional arrest changes RHAU localization to nucleolar caps, where it is 
co-localized with other RNA helicases, p68 and p72. This suggests that RHAU is 
involved in transcription-related RNA metabolism in the nucleus. 
 
The discovery that RHAU is localized mainly in the nucleus prompted me to 
consider the nuclear functions of RHAU, which led to a second project using 
RHAU-knockdown. To see whether RHAU affects global gene expression either 
transcriptionally or posttranscriptionally, microarray analysis using total RNA 
prepared from RHAU-depleted HeLa cell lines was performed to measure both 
the steady-state mRNA level and mRNA half-life by actinomycinD-chase. Most 
transcripts whose steady-state levels were affected by RHAU knockdown showed 
no change in half-life, suggesting that these transcripts were the subject of 
transcriptional regulation.  
 
In cells depleted of RHAU using shRNA, retardation of growth was observed, 
especially when cells were stressed, for example, by serum-starvation. RHAU 
indeed affected more genes in starved conditions, suggesting the involvement of 
RHAU in cellular stress responses in mammalian cells.  
 
Overall, the results suggest that each RNA helicase is involved in various cellular 
processes. RHAU has dual functions, being involved in both the synthesis and 
degradation of mRNA in different subcellular compartments. Thus, my work 
presents a novel view of RNA helicases as proteins with multiple functions in 
different cellular contexts. 
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Section 1  -  Introduction 
 
 
  
1.01. Regulation of gene expression at different steps 
 
Control of gene expression in 
eukaryotes is a complex process 
involving numerous steps, from 
the binding of transcription 
factors to their target sequence 
to the post-translational 
modification of proteins. Specific 
factors, either proteins or 
functional RNAs, are involved at 
each step to maintain cellular 
homeostasis in changing 
environments. Figure 1 
illustrates six steps important for 
the control of gene expression in 
eukaryotic cells. In principle, all 
steps leading from DNA to 
protein can be regulated and will 
influence total protein activity. 
The initial transcriptional 
control is of paramount 
importance to the expression of 
most genes because only this 
step can result in “on” or “off” of 
RNA synthesis, which 
dramatically changes protein 
levels. The subsequent steps 2-4 
are regulatory steps acting on mRNA. Many mammalian mRNAs require pre-
mRNA splicing and some are processed or edited. These steps, including 
alternative splicing, contribute to variation in mRNA. Since maturation of 
mRNAs is required for nuclear export and mRNA stability, malfunction of these 
mechanisms is coupled to abnormal states of gene expression. The third step of 
mRNA transport is important for maintaining RNA quality because it ensures 
that all nuclear metabolic events of mRNAs are completed prior to export from 
the nucleus. Thus, this step is intimately connected to other steps in RNA-
metabolism. Some mRNAs must be transported to specific locations in the 
cytoplasm, resulting in localized protein synthesis (St Johnston 2005). The fourth 
step of mRNA degradation changes cytoplasmic concentrations of mRNA more 
directly. This is a highly regulated step responsible for determining mRNA 
amount and turnover. Gene silencing mediated by small RNAs like micro RNAs 
(miRNAs) is also based on mRNA degradation as well as the suppression of 
 
 
 
 
Figure 1. Six steps at which eukaryotic gene expression can 
be controlled.  
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translation, both of which have a large impact on total protein. The rate of 
translation is also regulated and varies depending on cellular conditions. Finally, 
post-translational modifications, such as phosphorylation, methylation and 
acetylation, regulate protein activities, and protein degradation, e.g. by ubiquitin-
dependent proteolysis, is also highly regulated depending on the cellular status.  
 
It is, therefore, important to consider the regulation of these different steps when 
investigating control of gene expression. Referring to total mRNA, at least the 
two different parameters of synthesis and degradation must be considered. As 
discussed in the next section, not only the rate of transcription but also the 
regulation of mRNA degradation can greatly affect fine-tuning of gene expression 
in eukaryotic cells. Importantly, there is evidence for cross-talk between these 
different steps (Reed 2003). For example, factors of the general transcription 
machinery, such as the C-terminal domain of RNA polymerase II (CTD) and the 
transcription elongation factor TAT-SF1, associate with components of the 
splicing pathway (Abovich and Rosbash 1997; Morris and Greenleaf 2000; Fong 
and Zhou 2001). mRNA export is also physically and functionally linked to 
transcription and splicing: export factors are loaded on to synthesized mRNAs co-
transcriptionally (Strasser et al. 2002; Vinciguerra and Stutz 2004; Kohler and 
Hurt 2007). The coupling of cellular pathways requires the interaction of 
molecules involved in the different pathways and this is achieved by regulated 
intracellular transport of molecules by energy-dependent mechanisms. In this 
thesis, I report on the investigation of one particular protein that associates with 
RNA and various proteins at different cellular locations. The study was initiated 
with the single question of why this molecule is actively translocated into 
different cellular compartments. The results I report here do not fully answer the 
question but suffice to put forward the hypothesis that the protein is transported 
to fulfil different functions in different intracellular locations and also that it 
mediates between different steps of RNA metabolism through its association with 
various molecules.  
   
 
 
1.02. Regulation of mRNA stability 
 
1.02.01. Regulation of mRNA stability contributes to changes of gene expression.  
 
Regulation of gene expression at the level of mRNA stability is an important and 
highly regulated process. Half-lives vary considerably between mRNA species. In 
yeast, mRNA half-lives range from 1 min to more than 100 min (Gouka et al. 
1996) and in mammalian cells from less than 20 min to over 50 h (Stolle and 
Benz 1988). For a given mRNA molecule, stability changes in response to 
extracellular stimuli. T cell activation, for example, dramatically stabilizes 
lymphokine mRNAs, such as IL2, GM-CSF, INF-γ, and TNF-α, contributing to 
increases in total mRNA (Lindstein et al. 1989). Global gene expression analyses 
using microarrays have revealed that regulation of mRNA stability accounts for 
about 50% of all changes in response to cellular signals (Fan et al. 2002; Cheadle 
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et al. 2005). These data all clearly suggest the existence of a mechanism to 
maintain and regulate mRNA stability in cells.  
 
The rapid induction as well as reversal of gene expression allows prompt changes 
in mRNA steady-state levels in response to changing environmental conditions. 
Transiently expressed genes, early response genes, are induced by various 
cellular stimuli, with transcript levels increasing as much as 50-fold in a short 
time. Change in mRNA stability is especially critical for the rapid reduction of 
mRNA following induction, as a reduction of transcription rate alone is not 
sufficient to quickly reduce cellular mRNA levels. Microarray analysis has shown 
that 74% of mRNAs that declined in response to stress did so not by inactivation 
of transcription but by mRNA destabilization (Fan et al. 2002). Computational 
models also predict that the best strategy to reduce cellular mRNA concentration 
is a decrease in half-life. Conversely, induction of transcription rather than 
stabilization of mRNAs seems to be effective for increasing mRNA concentration 
in a short time (Perez-Ortin et al. 2007).  
 
 
 
1.02.02. mRNA degradation machinery  
 
Most mRNAs in eukaryotes are 5’-capped and 3’-polyadenylated. These mRNA 
modifications occur shortly after initiation of transcription and are both 
important in the protection of mRNAs from exonucleolytic degradation. Poly(A) 
tail shortening is often the initial and rate-limiting step of mRNA degradation in 
yeast and mammalian cells. Three independent complexes possessing poly(A)-
specific 3’-exoribonuclease activities exist in most eukaryotic cells but yeast and 
Drosophila contain only two, CCR4-CAF1 and PAN2-PAN3. In mammalian cells, 
these two complexes represent the major cytoplasmic deadenylation activity 
(Yamashita et al. 2005). Decay of both stable and nonsense-codon-containing 
unstable β-globin mRNAs is first initiated by the PAN2-PAN3 complex and then 
by CCR4-CAF1 in the second phase of deadenylation, which is followed by 
degradation of the mRNA body (Yamashita et al. 2005). In contrast, higher 
eukaryote-specific poly(A) exoribonuclease, PARN, seems to deadenylate specific 
sets of mRNAs, such as those containing AU-rich elements (ARE). It has been 
shown that PARN catalyses ARE-dependent deadenylation in vitro (Lai et al. 
2003).  
 
As soon as poly(A) is removed, mRNA is destined for rapid exonucleolytic decay, 
either from the 5’ or 3’ end. The 5’-to-3’ decay pathway starts by removal of the 
cap by decapping protein 2 (DCP2) together with the other activators DCP1, 
LSM1-7 complex and Pat1. Following decapping, 5’-to-3’ exoribonuclease XRN1 
digests the mRNA body (Wilusz et al. 2001; Meyer et al. 2004). In the other 
pathway, deadenylation is followed by 3’-to-5’ decay of the RNA body mediated by 
the exosome. The exosome consists of 9-11 subunits of 3’-to-5’ exonucleases 
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forming a donut-like structure that progressively phosphorylizes the mRNA body 
from 3’ ends (Liu et al. 2006).  
 
Although deadenylation-dependent exonucleolytic decay is the major mRNA 
degradation pathway in eukaryotes, mRNAs such as for insulin-like growth 
factor 2 (IGF2), c-myc, and transferrin receptor are degraded by endonucleolytic 
activities independent of deadenylation (Bernstein et al. 1992; Binder et al. 1994; 
Scheper et al. 1995; Scheper et al. 1996). This process is mediated by specific 
endonucleases and particular sets of mRNAs, often in response to extracellular 
stimuli. Endoribonuclease RNaseL, for example, plays an important role in viral 
infection and the interferon response (Silverman 1994; Li et al. 1998; Li et al. 
2000).  
 
 
 
1.02.03. cis-element  
 
mRNA stability is controlled by regulatory cis-acting elements on transcripts and 
their trans-acting binding proteins (Ross 1995; Guhaniyogi and Brewer 2001). 
Cis-acting elements are frequently found in 3’-untranslated regions (UTR), for 
example, of AU-rich elements (ARE; a destabilizing element) (Chen and Shyu 
1995), iron-response elements (IRS; an iron-regulatory element also found in 
5’UTR) (Thomson et al. 1999), constitutive decay elements (CDE, a destabilizing 
element) (Stoecklin et al. 2003), pyrimidine-rich elements (stabilizing elements of 
α-globin, β-globin, and α-collagen) (Kiledjian et al. 1995; Yu and Russell 2001; 
Lindquist et al. 2004) and others (Guhaniyogi and Brewer 2001). Regulatory 
elements are also found in the 5’UTR and even in protein-coding regions such as 
the c-jun response element in the 5’UTR of IL-2 mRNA (Chen et al. 1998) and 
coding elements of c-myc mRNA, which destabilize the message (Yeilding and 
Lee 1997). Each element associates with specific binding partners that can 
recruit or avoid associating mRNAs to/from degradation complexes, depending on 
the cellular conditions, thus regulating mRNA stability. 
 
 
 
1.03. AU-rich element-mediated mRNA decay (AMD) 
 
1.03.01. AU-rich element 
 
By far the best-studied cis-element is ARE, located in the 3’UTR of many 
transcripts encoding, for example, cytokines, proto-oncogenes and transcription 
factors (Khabar 2005). In 1986, a conserved sequence enriched with adenylate 
and uridylate was found in the 3’UTR of mRNAs encoding inflammatory 
mediators (Caput et al. 1986). This sequence was shown later to be responsible 
for the instability of granulocyte macrophage-colony stimulating factor (GM-CSF) 
message since it elicited the rapid decay of otherwise stable β-globin reporter 
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mRNA (Shaw and Kamen 1986). Subsequently, the ARE has been characterized 
as an instability regulatory element for numerous mRNAs encoding proteins with 
diverse cellular functions. A database of ARE-containing mRNAs predicts that 5-
8 % of human genes encode transcripts containing AREs (Bakheet et al. 2006). 
AREs vary in sequence and length but most contain one or more copies of the 
octamer UUAUUUAU, the AUUUA core sequence of which is essential for the 
mRNA destabilization elicited by AREs. According to the classification by Chen 
and Shyu (Chen and Shyu 1995), class I AREs contain 1-3 non-tandem copies of 
the pentanucleotide AUUUA embedded within a U-rich region. Class II AREs 
contain two or more reiterated copies of this motif and class III ARE, exemplified 
by that found in c-jun mRNA, are U-rich sequences lacking AUUUA motifs (Peng 
et al. 1996).   
 
 
 
1.03.02. Degradation machinery and AUBPs 
 
To elicit rapid degradation, ARE must be recognized by the mRNA degradation 
machinery. ARE-RNA itself can interact with the exosome component PmScl-75 
(Mukherjee et al. 2002) and the in vitro reconstituted exosome drives efficient 
degradation of AU-containing RNA but not the generic RNA without ARE (Liu et 
al. 2006). This suggests that ARE-RNA has a higher affinity for the exosome than 
other stable mRNAs. However, the in vitro reconstituted exosome does not 
degrade poly(A)-tailed mRNA efficiently (Liu et al. 2006), whereas the 
immunopurified exosome from HeLa cells can degrade ARE-RNA with poly(A) 
tails (Chen et al. 2001), suggesting that further factors in addition to the exosome 
are required for efficient deadenylation and decay of ARE-RNA. A group of 
proteins termed ARE-binding proteins (AUBPs) with affinity for ARE has been 
shown to mediate AMD. Three AUBPs, 37-kDa isoforms of AUF1, KSRP, and 
tristetraprolin (TTP), have affinity for the exosome and the latter two factors are 
required for exosome-mediated AMD. TTP and its binding partner BRF1 are also 
involved in the 5’-to-3’ decay pathway, since they interact with a decapping 
complex (Kedersha et al. 2005; Lykke-Andersen and Wagner 2005). It has been 
shown that ARE stimulates decapping activity in HeLa cells (Gao et al. 2001). 
Furthermore, ARE-RNA is detected in cytoplasmic processing bodies (P-bodies), 
colocalizing with TTP, BRF1, and DCP1. P-bodies are cytoplasmic foci containing 
many components of 5’-to-3’ decay pathways, including XRN1, DCP1, and the 
LSM complex but not the exosome (Franks and Lykke-Andersen 2007), which 
suggests that ARE-RNA is degraded in P-bodies by the 5’-to-3’ decay machinery. 
However, Lin et al reported that ARE-RNA is also present in distinct cytoplasmic 
granules containing the exosome (Lin et al. 2007). Furthermore, a significant but 
diffuse amount of ARE-RNA is found in the cytosol, suggesting that P-bodies may 
not be the only site of AMD (Lin et al. 2007).  
 
It is currently unclear which pathways of exonucleolysis, either from the 5’ or 3’ 
end, contribute to AMD in mammalian cells. In siRNA approaches to 
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downregulate individual decay factors in HeLa cells, two groups (Stoecklin et al. 
2006; Lin et al. 2007) showed that knockdown of the 5’-to-3’ pathway components 
XRN1 and LSM1 as well as the exosome components PmScl-75 and Rrp46 
impaired AMD. Downregulation of two factors, one involved in 5’-to-3’ and 
another in 3’-to-5’ decay, produced the largest impairment of AMD, implying that 
both pathways are active in AMD and that some are not redundant. In addition 
to these two distinct pathways, miRNA-mediated gene silencing has also been 
implicated in AMD in Drosophila and HeLa cells. RISC complexes, required for 
miRNA and siRNA-mediated gene silencing, are directed to ARE-RNA by 
imperfect base pairing between miR-16 and AREs, which eventually facilitates 
degradation of ARE-RNA (Jing et al. 2005). Most recently, ARE has been 
implicated in upregulation of translation by fragile-X mental-retardation-related 
protein 1 (FXR1) and an essential miRNA-loading factor, Argonaute2 (Vasudevan 
and Steitz 2007). A relationship between ARE and translational regulation has 
also been described in another pathway, in which HuR (an AUBP) suppresses 
miRNA-mediated translational repression (Bhattacharyya et al. 2006). Although 
the direction of ARE-mediated translational regulation may vary and the 
mechanism itself is not yet fully understood, these reports suggest that ARE is a 
mediator of mRNA degradation and translation. Interestingly, not only ARE-
RNAs are localized in P-bodies but also miRNAs and miRNA-regulatory factors 
(Liu et al. 2005; Eulalio et al. 2007). ARE-RNA may affect gene expression in 
various ways in specific cytoplasmic locations. 
 
 
 
1.04. RHAU : RNA helicase-associated with AU-rich element 
 
RHAU (alias: DHX36) is a putative RNA helicase identified by RNA-affinity 
chromatography using ARE of uPA mRNA and human HeLa nuclear extracts 
(Tran et al. 2004). It was termed RHAU for “RNA helicase-associated with AU-
rich elements” since it contains DExH-conserved motifs giving rise to the 
putative RNA helicase activity. 
 
1.04.01. RHAU as a destabilizing factor of ARE-RNA.  
 
As RHAU has a specific affinity for the ARE sequence of mRNA, the effect of 
RHAU on AMD was studied first. In HeLa cells, overexpression of RHAU caused 
destabilization of reporter ARE (β-globin mRNA harbouring uPA-ARE) as well as 
endogenous uPA mRNA. Examination of the in vitro mRNA decay system also 
showed that recombinant RHAU protein accelerates deadenylation and decay of 
β-globin-AREuPA. In contrast, downregulation of RHAU by siRNA in HeLa cells 
stabilized the reporter ARE. It was concluded that RHAU is a factor promoting 
degradation of ARE-containing mRNAs. RHAU requires ATPase activity, since 
the mutant E335A, which is unable to hydrolyze ATP, has no effect on the decay 
of AREuPA either in vivo or in vitro. In this study, a destabilizing effect of RHAU 
was found for uPA-ARE but not other types of mRNA, e.g. for the uPA receptor, 
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which contains a different class of ARE. This suggests that RHAU has a specific 
role in AMD (Tran et al. 2004).  
 
1.04.02. RHAU as a G4 DNA resolvase.  
 
In 2005, Akman’s group isolated RHAU as the major source of guanine 
quadruplex (G4) DNA-resolving activity in HeLa cell lysates (Vaughn et al. 2005). 
G4 DNA is a highly stable DNA structure composed of several layers of a guanine 
tetrad in which four guanine residues from the same or different strands are 
linked by Hogsteen-type hydrogen bonding (Maizels 2006). G4 structures are 
expected to occur in guanine-rich regions such as telomeres, ribosomal DNA, and 
immunoglobulin class switch regions, as well as in the promoter regions of 
several proto-oncogenes such as c-myc and c-kit, the transcriptional activity of 
which is repressed by this structure (Siddiqui-Jain et al. 2002; Maizels 2006; 
Shirude et al. 2007). Therefore, G4-resolving activity is expected to activate the 
transcription of genes containing G4 in the promoters. However, the biological 
functions of G4-DNA and G4-resolving enzymes (G4-resolvase) in vivo are largely 
unknown and the physiological significance of RHAU G4 resolvase activity has 
also not been defined.  
   
 
 
1.04.03. Affinity to other molecules - protein and RNA 
 
Several RNA-related proteins have been found to interact with RHAU either via 
RNA or not. Examples of mRNA degradation factors include the exosome 
components, PM/Scl100 and hRrp40p, and poly(A) ribonuclease PARN, which 
interact with RHAU even in the absence of RNA (Tran et al. 2004). It was 
suggested, therefore, that RHAU first promotes deadenylation of ARE-RNA, and 
then recruits it into the exosome for rapid degradation. RHAU also interacts with 
further AUBPs, namely NF90 and HuR, that were co-precipitated in the initial 
RNA-affinity chromatography by which RHAU was isolated. These AUBPs both 
interact with RHAU in a manner dependent on RNA. In the case of NF90, strong 
interaction was observed in the presence of uPA-ARE but not IL2-ARE or 
mutated uPA-ARE. Downregulation of NF90 stabilized uPA-ARE. Thus, it is 
likely that both proteins have very specific roles in promoting decay of uPA-
mRNA (Akimitsu, unpublished data). 
 
RHAU was first isolated from HeLa nuclei with uPA-ARE oligonucleotides (Tran 
et al. 2004). However, in vitro RNA electrophoretic mobility shift assays 
(REMSA) using recombinant RHAU protein and ARE-uPA showed that RHAU by 
itself has little interaction with ARE. The interaction was observed more clearly 
when protein and RNA were crosslinked, suggesting that RHAU interacts with 
RNA only transiently (Akimutsu and Lattmann, unpublished data). It seems that 
additional proteins are required for a more stable association of RHAU with RNA. 
One such protein is NF90. The intensity of the interaction of RHAU with uPA-
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ARE was increased 2.7-fold by addition of recombinant NF90. Unlike RHAU, 
NF90 itself has strong affinity for uPA-ARE and, thus, NF90 may promote the 
interaction between RHAU and ARE that is required to stimulate mRNA 
degradation (Akimitsu, unpublished data).   
 
 
 
1.04.04. Evolutional conservation and expression pattern.  
 
According to sequence alignment data, RHAU is found in every clade in the 
Metazoa except for the phylum Nematode. The yeast DEAH-box protein 
YLR419w shows similarity to five human DExH proteins, including RHAU. Thus 
YLR419w is probably a common ancestor of these proteins (see Figure 2). 
YLR419w is dispensable in yeast and has not been characterized so far (Colley et 
al. 2000). RHAU is highly conserved, especially in vertebrates, through the 
central helicase core motifs and the C-terminal extremity but not the N-terminus, 
suggesting that the N-terminal domain is involved in its specific function in 
higher eukaryotes (Lattmann, unpublished data).  
In humans, RHAU is moderately expressed in most tissue and cell types but is 
especially highly expressed in lymphocytes such as T-, B-, and NK cells, as well 
as in their precursors (Human GeneAtlas GNF1H, 
http://symatlas.gnf.org/SymAtlas/). Northern blot analyses of various mouse 
tissues showed highest expression of RHAU in thymus, also suggesting a possible 
role for RHAU in the immune system (Akimitsu, unpublished data). Bone 
marrow and blood were not tested. Many mRNAs encoding cytokines in immune 
cells contain ARE sequences and their expression is tightly controlled by mRNA 
degradation. RHAU may be involved in such regulation in lymphocytes.  
  
 
 
1.04.05. Intracellular localization.  
 
RHAU was originally identified in HeLa nuclear extracts. Ectopically expressed 
HA-RHAU was predominantly localized in the nuclei of HeLa cells (Tran et al. 
2004). This localization pattern raised the possibility that RHAU has other 
functions in the nucleus, since mature mRNA degradation occurs in the 
cytoplasm or in cytoplasmic bodies. This hypothesis will be discussed further.  
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1.05. RNA helicases   
 
1.05.01. Structure.  
 
RNA helicases are ATP-hydrolytic enzymes found in virus, bacteria, archaea and 
eukaryotes, where they are the largest protein family involved in RNA 
metabolism (Anantharaman et al. 2002). All currently known RNA helicases 
belong to the helicase superfamilies 1-4, which include both DNA and RNA 
helicases. They share a highly conserved helicase domain consisting of several 
motifs (Tanner and Linder 2001; Linder 2006). A few RNA helicases belong to 
helicase superfamily 1 (SF1), including Upf1, an enzyme required for nonsense-
mediated decay (NMD), but most RNA helicases belong to helicase superfamily 2 
(SF2). RNA helicases in SF2 are further classified into three groups, DEAD-box, 
DEAH-box and DExH-box, based on the amino acid sequence of motif II in the 
helicase domain. In humans, DEAD-box proteins have the gene symbol of DDX-, 
whereas DEAH and DExH-box proteins are designated as DHX- (Abdelhaleem et 
al. 2003). RHAU belongs to the DExH-box protein family and, therefore, has the 
gene symbol of DHX36.  
 
DExH/D proteins contain at least eight conserved motifs (I, Ia, Ib, and II-VI) in 
the helicase core domain. These motifs have been characterized by biochemical 
approaches as they have ATP-binding and hydrolytic activity (I, II, VI), bind to 
nucleic acids (Ia, Ib, IV), or coordinate polynucleotide binding and ATPase 
activity (III and V) (Tanner and Linder 2001). Furthermore, recent studies of 
protein structure have provided more information on the helicase domain 
structure. Up to now, structures of two DEAD-box proteins, eIF4AIII (Andersen 
et al. 2006; Bono et al. 2006) and Vasa (Sengoku et al. 2006), and one viral 
DExH-box protein, HCV NS3 (Kim et al. 1998; Mackintosh et al. 2006), have 
been determined in the presence of nucleic acids. The helicase domain is formed 
by two domains connected via a flexible linker region. Without ATP or nucleic 
acids, the two domains are relatively open, especially in DEAD-box proteins. ATP 
and/or nucleic acid binding bring the two domains into a more defined 
arrangement (Jankowsky and Fairman 2007). Thus, it is possible that binding to 
nucleic acid promotes ATP binding and hydrolysis and vice versa. Many DEAD-
box proteins are in fact unable to bind or hydrolyze ATP without RNA (Lorsch 
and Herschlag 1998; Iost et al. 1999; Polach and Uhlenbeck 2002; Talavera and 
De La Cruz 2005). DExH proteins, in contrast, show ATP hydrolysis without 
RNA, although RNA can still stimulate ATP hydrolysis (Shuman 1992; Tanaka 
and Schwer 2005; Tanaka and Schwer 2006). The DExH protein HCV NS3 
indeed shows less dramatic movements upon binding to ATP and nucleic acid 
(Kim et al. 1998; Jankowsky and Fairman 2007). Whether RNA-dependent or not, 
changes in conformation caused by binding to ATP seem to be an important 
feature of RNA helicases when acting as ATP-driven switches at specific points of 
RNA metabolism. 
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1.05.02. helicase and RNPase.  
 
DExH/D proteins are characterized as ATP-dependent RNA helicases since some 
of the proteins, but not all, exhibit unwinding activity on duplex RNA molecules 
in vitro. The unwinding activity of viral DExH protein HCV NS3 has been 
monitored at the single-molecule level using a 60-bp RNA hairpin, which 
supported the model that DExH proteins first load onto the single-strand region 
of RNA and then translocate along one of the strands in a unidirectional and 
progressive fashion (Dumont et al. 2006). In contrast to the viral DExH proteins 
that can unwind several dozen base pairs, DEAD-box proteins are normally 
unable to unwind long duplexes but only a few base pairs, in a manner different 
to that of DExH proteins (Jankowsky et al. 2000; Cordin et al. 2006). DEAD-box 
protein Ded1 directly loads onto the duplex region and spontaneously initiates 
strand dissociation from the loading region. Single-strand regions increase the 
efficiency of duplex unwinding but this facilitates the loading of enzymes rather 
than loading onto the single-strand region itself (Yang and Jankowsky 2006). The 
physiological importance of duplex RNA unwinding activity has been less 
characterized than the biochemical unwinding experiments. For some RNA 
helicases, helicase activity is clearly required for the biological role. Dbp4p 
dissociates duplexes of U14 snoRNA and pre-rRNA, and thus duplex-unwinding 
activity is required for release of U14 from pre-ribosomes, an essential step in the 
pre-rRNA processing pathway (Kos and Tollervey 2005). However, the actual 
substrates of many other RNA helicases are unknown and, thus, the relevance of 
their unwinding activity for their biological function has not been clarified, even 
though they unwind duplexes in vitro (Tanner and Linder 2001; Cordin et al. 
2006; Linder 2006).  
 
The results of recent studies suggested that the activity of RNA helicases is not 
restricted to rearrangement of RNA secondary structure, but that it includes the 
modification of protein-RNA interactions (Jankowsky and Bowers 2006). Two 
proteins, viral DExH NPH-II and yeast DEAD-box protein DED1, have been 
shown to dissociate proteins from RNA in an ATP-dependent fashion with four 
different substrate RNPs in vitro (Jankowsky et al. 2001; Fairman et al. 2004; 
Bowers et al. 2006). Although the dissociation rate constant depends on various 
helicases and substrates, both proteins are able to displace exon junction complex 
(EJC), a protein complex bound upstream of exon-exon junctions, from the single-
stranded spliced mRNAs, indicating that unwinding activity is not required for 
this activity (Jankowsky et al. 2001; Fairman et al. 2004; Bowers et al. 2006). 
These authors have proposed a novel feature of RNA helicases as a remodeler of 
RNPs. Since RNAs are invariably complexed with various proteins, the 
rearrangement of RNA-protein interactions by an RNA helicase is likely to be a 
feature of every step of the RNA metabolic pathway. 
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1.05.03. Various functions of RNA helicases. 
 
RNA helicases are involved in all aspects of RNA metabolism. In yeast, almost all 
RNA helicases are essential for cell viability and there are orthologs for most of 
these proteins in mammals (de la Cruz et al. 1999). In humans, 38 DEAD-box 
helicases and 14 DExH-box helicases have been identified so far (Abdelhaleem et 
al. 2003; Linder 2006) and functions have been assigned in various steps of RNA 
metabolism. Four DExH helicases are involved in pre-mRNA splicing and one in 
ribosomal RNA processing; all of these are essential in yeast. Although YLR490w, 
an ancestor of five human DExH proteins including RHAU, is not essential for 
yeast viability, DHX9, which is also known as RNA helicase A (RHA) or NDH II 
and shares the same yeast ancestor, is required for mouse embryonic 
development (Lee et al. 1998). This suggests that RHA has gained additional 
functions during evolution.  
 
Whilst it looks as though a unique RNA helicase is engaged in each RNA 
metabolic step, many authors have reported that a single RNA helicase harbours 
multiple functions acting at different steps from transcription, splicing, and RNA 
export to mRNA stability (Fuller-Pace 2006). RHA is one such protein, playing 
many roles in the regulation of gene expression. In the nucleus, RHA interacts 
with RNA polymerase II and transcriptional regulators such as CBP/p300 
(Nakajima et al. 1997), BRCA1 (Anderson et al. 1998) and NF-κB (Tetsuka et al. 
2004), as well as promoters of the p16INK4a and MDR1 genes (Myohanen and 
Baylin 2001; Zhong and Safa 2004) and activates their transcription. RHA is also 
involved in RNA export mediated by the constitutive transport element (CTE) 
(Tang et al. 1997; Tang et al. 1999), in RNA splicing by interacting with SMN 
(survival motor neuron complex), and in the translation of selected mRNAs 
(Hartman et al. 2006; Bolinger et al. 2007). Most recently, RHA has been 
identified also in the RNA-induced silencing complex (RISC) in HeLa cells, 
functioning as an siRNA-loading factor (Robb and Rana 2007).  
 
In another case, DEAD box proteins p68 (DDX5) and p72 (DDX17) have been 
shown also to regulate transcription via interaction with various transcription 
regulators, such as β-catenin (Yang et al. 2006), MyoD (Caretti et al. 2006), 
Smads (Warner et al. 2004), HDAC1 (Wilson et al. 2004), and p53 (Bates et al. 
2005). They, thus, play a role in epithelial mesenchymal transition, myogenesis, 
regulation of apoptosis, general transcriptional repression, and tumorigenesis, 
respectively. Furthermore, it has also been suggested that they are required for 
pre-mRNA splicing (Liu 2002; Lin et al. 2005) and alternative splicing (Guil et al. 
2003) as well as the processing of rRNA and miRNAs (Fukuda et al. 2007). These 
observations indicate that a single RNA helicase plays many different roles, 
depending on interactions with various molecules in different cellular 
environments. 
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Figure 2. Human DExH proteins. Amino acid sequences of fourteen human DExH proteins were aligned by an online 
program, MAFFT ver.6 (http://align.bmr.kyushu-u.ac.jp/mafft/online/server/). Graphic tree was made based on the sequence 
distances between each protein using Tree View 1.6.6. Essential (in red): lethal phonotype described in knockout organisms. 
Not essential (in blue):  knockout organisms are not lethal. Lattmann, unpublished data.  
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1.06. Spatial controls of RNA and proteins involved in RNA metabolisms.  
 
Compartmentalization is one of the most important features of cells. Eukaryotic 
cells are themselves surrounded by a plasma membrane that fulfils specific roles 
but they also include many different compartments, like organelles, each of 
which contains a characteristic set of enzymes and other molecules active in its 
specialized role. The nucleus, for example, stores compacted DNA and enzymes to 
synthesize mRNAs. The nuclear membrane separates the sites of RNA synthesis 
and protein synthesis, thus avoiding the translation of premature mRNAs to 
proteins. Further subdomains have been characterized inside organelles or in the 
cytosol. These cellular “bodies” are not surrounded by membranes but by a local 
accumulation of selected molecules that can be visualized by specific markers. 
The cytosol contains P-bodies as well as stress granules formed in response to 
stress. Both bodies contain mRNA and specific RNA-binding proteins and 
function as sites of mRNA degradation (P-body), mRNA storage (stress granule), 
and suppression of translation (both of these organelles) (Anderson and Kedersha 
2002; Kedersha et al. 2005; Eulalio et al. 2007; Parker and Sheth 2007). The 
nucleus is more complex than the cytoplasm, fulfilling many different roles in a 
small space, such as storage of genomic DNA, synthesis, processing, and export of 
RNA, as well as the degradation of premature and incorrectly processed RNAs. 
Therefore, it has been suggested that the nucleus has a very precise layout that 
ensures the efficiency of assorted nuclear activities. Many nuclear bodies have 
been characterized, such as nuclear speckles involved in the storage, assembly, 
and modification of pre-mRNA splicing factors, PML bodies playing a role in 
transcriptional regulation of specific genes, cajal bodies involved in snRNP and 
snoRNP biogenesis and posttranscriptional modification of newly assembled 
spliceosomal snRNAs, and polycomb bodies containing silencing proteins, etc. 
The numbers and sizes of these nuclear bodies vary depending on cell type and 
conditions, which suggest that they are involved in regulatory steps of cellular 
metabolism (Matera 1999; Lamond and Sleeman 2003; Matera and Shpargel 
2006).  
 
 
  
Aims 
 
23 
Aims 
 
 
 
 
 
 
To understand biological role(s) of RHAU in mammalian cells.  
 
 
 
 
 
  To determine subcellular localization of RHAU and its regulations.  
 
 
  To determine RHAU target genes and mRNAs.  
 
 
  To determine the effect of RHAU-depletion in mammalian cells.  
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Section 2  -  Materials and Methods 
 
2.01. Plasmids 
 
Oligonucleotides used in this work are presented in Appendix I. 
Plasmid pTER was kindly provided by Hans Clevers (van de Wetering et al. 
2003). To construct pTER-shRHAU1 and pTER-shRHAU2, annealed 
oligonucleotides of shRHAU1-s, shRHAU2-s and shRHAU1-as, shRHAU2 were 
inserted into BglII/HindIII sites of the pTER vector to target RHAU mRNA at 
the site 1344-1364 nt and 2570-2590 nt, respectively. pTER-shLuc was kindly 
provided by A. Hergovich and B.A. Hemmings (Hergovich et al. 2007).  
To derive the N-terminal fusion plasmid pEGFP-RHAU, full-length RHAU was 
cut out from pcDNA3-HA-RHAU (Tran et al. 2004) using BamHI/XhoI and 
inserted into the BglII/SalI sites of pEGFP-C1 (Clontech laboratories, Inc., 
Mountain View, CA). To introduce the ATPase-deficient mutation, pEGFP-
RHAU-E335A was made using site-directed mutagenesis with oligonucleotides 
(E335A-s and E335A-as) that mutate the Glu335 of RHAU to Ala. To derive 
RHAU truncated mutants with N-terminal EGFP-tags, truncated forms of RHAU 
cDNAs were amplified by PCR using specific primers containing restriction sites 
and inserted into the BglII/EcoRI sites of pEGFP-C1. To derive the C-terminal 
fusion plasmids pRHAU-EGFP and pRHAU-E335A-EGFP, full-length RHAU 
was amplified by PCR using the primers RHAU 2 fw BamHI and RHAU1008 rv 
EcoRI with the plasmids pcDNA3-HA-RHAU and EGFP-RHAU-E335A, 
respectively, and inserted into the BamHI/EcoRI sites of pEGFP-N1 (Clontech). 
pcDNA3-Flag-RHAUsm was made by replacing the HA tag of pcDNA3-HA-
RHAU in HindIII/BamHI sites with annealed oligonucleotides coding the Flag 
sequence. To introduce silent mutations in the RHAU expression vector at the 
shRHAU-targeting site, we did site-directed mutagenesis using oligonucleotides 
RHAUsm-s and RHAUsm-as to amplify, using PCR, a mutated vector that 
contained two point mutations, G1350A and A1353G. To derive pGEX-RHAU(1-
200aa), truncated RHAU was amplified by PCR using the primers RHAU 2 fw 
BamHI and RHAU 200 rv EcoRI with the plasmid pcDNA3-HA-RHAU and 
inserted into BamHI/EcoRI sites of pGEX-2T (GE health care life sciences). To 
derive pcDNA3-HA-p68 and pcDNA3-HA-p72, full-length cDNA of p68 and p72 
were amplified using the primers p68-fw/p68-rv and p72-fw/p72-rv, respectively, 
using cDNA derived by reverse transcription of purified HeLa total RNA, and 
inserted into BamHI/XhoI sites of the pcDNA3.1(+)-HA vector. pcDNA3.1(+)-HA 
was made by inserting the annealed oligonucleotide fragment coding the HA 
sequence into the HindIII/BamHI sites of the pcDNA3.1(+) vector (Invitrogen 
Corporation, Carlsbad, CA). pcDNA3.1-HDAC1FLAG and pcDNA3.1-HDAC3FLAG 
were kindly from P. Matthias (FMI). The sequences of all plasmids made by PCR-
cloning were confirmed.  
 
2.02. Cell culture and transfection 
 
HeLa cells and COS7 cells were maintained in Dulbecco’s Modified Eagle’s 
Medium (DMEM), supplemented with 10% fetal calf serum at 37°C in the 
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presence of 5% CO2. T-RExTM-HeLa cells (Invitrogen) were maintained as above 
with the additional supplement of 3 μg/ml blasticidine (Invitrogen). T-RExTM-
HeLa cells were stably transfected with pTER-shRHAU or pTER-shLuc vectors 
using FuGENE6 (Roche Applied Science, Rotkreuz, Switzerland) and selected 
with zeocin (InvinoGen, San Diego, CA) at a final concentration of 450 μg/ml. 
Zeocin-resistant colonies were picked up as independent clones. The independent 
clones from same transfections were pooled in some experiments. To induce 
shRNA expression, cells were treated with doxycycline (Sigma-Aldrich Co.) at a 
final concentration of 1 μg/ml. HeLa-shRHAU1 cells, stably transfected with 
pTER-shRHAU1, were used in all experiments except Figure 22. They are 
indicated as HeLa-shRHAU cells in these figures. In Figure 22, two different cell 
lines targeting different region of RHAU mRNA, HeLa-shRHAU1 (same cell line 
as HeLa-shRHAU in the other figures) and HeLa-shRHAU2 that were stably 
transfected with pTER-shRHAU1 and pTER-shRHAU2, respectively, were used. 
Transient transfection of plasmid DNA using FuGENE6 was performed 
according to instructions provided by the manufacturer. We used 1 μg plasmid 
DNA and 3 μl FuGENE6 per 35-mm dish. 
 
2.03. Antibodies  
 
Mouse anti-RHAU monoclonal antibody was generated against a peptide 
sequence which corresponds to the C terminal of RHAU, aa991-1007, and which 
has previously been reported (Vaughn et al. 2005). Rabbit anti-H3-K9 
trimethylation and rabbit anti-NDH II (RNA helicase A) antibodies were kindly 
provided by A.H. Peters (Peters et al. 2003) and S. Zhang (Zhang et al. 1995), 
respectively. Commercially obtained antibodies were: mouse anti-DRBP76 (for 
detecting NF90) and mouse anti-Cleaved PARP (Asp214) from BD Biosciences 
(San Jose, CA), mouse anti-TRF2 (4A794) from Novus Biologicals, Inc. (Littleton, 
CO), rabbit Cleaved Caspase-3 (Asp175) from Cell Signaling Technology, Inc. 
(Danvers, MA), mouse anti-HDAC1 (2E10) from Millipore Corporation (Billerica, 
MA), rabbit anti-Histone H3 from Abcam plc. (Cambridge, UK), mouse anti-Ku 
(p80) (Ab-2, Clone111) from Lab vision Corp. (Fremont, CA), rabbit anti-BTF 
antibody (BL2521) from Bethyl Laboratories, Inc. (Montgomery, TX),  mouse 
anti-β-tubulin, mouse anti-SC35, and mouse anti-FLAG® M2 from Sigma-Aldrich 
Co. (St. Louis, MO), and mouse anti-GAPDH (6C5), goat anti-ERK1 (C-16)-G, 
rabbit anti-CRM1 (H-300), mouse anti-Oct1 (E-8), rabbit anti-hnRNP C1/C2 (H-
105), rabbit anti-HA (Y-11), and mouse anti-GFP (B-2) from Santa Cruz 
Biotechnology, Inc. (Santa Cruz, CA). Mouse antibodies were all monoclonal 
antibodies. 
 
2.04. Protein extraction and Western blotting 
 
To prepare total cell lysates, cells were lysed with NP40 buffer (50 mM Tris-HCl, 
pH 7.4, 120 mM NaCl, 1% NP-40, 1 mM EDTA, 5 mM Na3VO4, 5 mM NaF, 0.5 
μg/ml aprotinin, 1 μg/ml leupeptin) on ice for 30 min and centrifuged at 11,000 × 
g for 5 min at 4°C to remove cell debris. Typically, 20 μg of the total cell lysate 
were loaded for Western blotting. Nuclear fractionation was followed by Fey’s 
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protocol as previously described (Fey et al. 1986). HeLa cells were collected using 
PBS and subsequently lysed with CSK buffer (10 mM PIPES, pH 6.8, 50 mM 
NaCl, 300 mM sucrose, 3 mM MgCl2, 1 mM EGTA, 0.5 % Triton-X100) with 
Complete® (EDTA-free) (Roche Applied Science) for 3 min on ice and centrifuged 
at 650 × g  for 5 min. The pellet was dissolved in the nuclear extraction buffer (10 
mM PIPES, pH 6.8, 300 mM sucrose, 3 mM MgCl2, 1 mM EGTA, 0.5 % Triton-
X100, 0.25 M (NH4)2SO4) with Complete®, left for 5 min on ice and then 
centrifuged at 1000 × g  to obtain soluble (supernatant) and chromatin-rich 
(pellet) fractions. Each fraction was mixed with SDS-PAGE loading buffer and 
sonicated briefly before loading into the SDS-PAGE for the Western blotting. To 
visualize the bands, we used either the direct infrared fluorescence detection 
method or the chemiluminescence method. For the fluorescent blots, IR dye 
800CW-conjugated secondary antibodies were used at a dilution of 1:10,000 and 
quantified using an Odyssey infrared imager (LI-COR Biosciences UK Ltd., 
Cambridge, UK). For the chemiluminescent blots, we used horseradish 
peroxidase (HRP)-conjugated secondary antibodies at a dilution of 1:4,000 and 
ECLTM western blotting detection reagents (Amersham Biosciences, Piscataway, 
NJ). The membranes were exposed to Kodak X-Omat LS films.  
 
2.05. Immunoprecipitation  
 
8×105 HeLa cells were seeded in 10 cm dishes and transfected the next day with 
total 6 μg of plasmids using 18 μl of FuGENE6. After 48 h of transfection, cells 
were collected and lysed with IP buffer (20 mM HEPES pH 7.5, 3 mM MgCl2, 150 
mM NaCl, 0.3% CHAPS) and briefly sonicated. To the lysates, 400U/ml RNasin 
(Promega Co., Madison, Wis.) or 10 μg/ml RNaseA plus 100 U/ml RNaseT1 was 
added. The lysate was suspended with anti-FLAG M2 affinity gel (Sigma-Aldrich 
Co.), rotated for 2 h at 4ºC, and then washed with the IP buffer. The precipitates 
were redissolved and loaded into SDS-PAGE for the Western blotting using anti-
FLAG and anti-HA antibodies.  
 
2.06. in situ extraction 
 
HeLa cells (8×104 cells per well) were seeded in 12-well plates with coverslips and 
transfected the next day with 500 ng of plasmids using FuGENE6. After 48 h of 
transfection, cells were washed with ice-cold PBS once and added 0.1 % Triton-
X100 in PBS for 5 min on ice to permeabilize plasma membranes. Permeabilized 
cells were further treated with DNase or RNase by adding 100 U/ml DNase I plus 
400 U/ml RNasin in CSK buffer or 20 μg/ml RNase A plus 100 U/ml RNase T1 in 
CSK buffer, respectively, and incubated at room temperature for 20 min. Cells 
were washed twice with PBS and fixed with 3.8 % paraformaldehyde in PBS for 
10 min at room temperature. Cells were further double stained using anti-BTF 
(transcription factor, (Haraguchi et al. 2004)) antibody to stain nucleus both in 
DNase- and RNase-treated cells as well as DAPI to confirm breakdown of DNA in 
DNase-treated cells. Images taken by confocal microscope were analyzed to 
obtain numbers of EGFP-positive cells out of about 200 cells visualized by the 
BTF-staining.  
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2.07. Immunocytochemistry and image processing 
 
HeLa cells (8×104 cells per well) were seeded in 12-well plates with coverslips and 
transfected the next day with 500 ng of plasmids using FuGENE6. For inhibition 
of transcription, Actinomycin D (ActD: AppliChem GmbH, Darmstadt, Germany) 
or dichlororibofuranosyl benzimidazole (DRB: Sigma-Aldrich Co) was added 2 h 
before fixation to a final concentration of 5 μg/ml or 25 μg/ml, respectively. Cells 
were fixed with 3.8% paraformaldehyde in PBS 48 h after transfection, 
permeabilized with 0.5% Triton-X100 in PBS and blocked with 5% horse serum 
in PHEM buffer (25 mM HEPES, 10 mM EGTA, 60 mM PIPES, 2 mM MgCl2, pH 
6.9). Cells were incubated with primary antibodies in the same buffer at 4ºC over 
night. Mouse anti-SC35, rabbit anti-H3 K9 trimethylation, rabbit anti-HA, rabbit 
anti-BTF, and mouse anti-TRF2 antibodies were used at dilutions of 1:4,000, 
1:500, 1:200, 1:400, and 1:500, respectively. We used Cy2TM, Cy3TM, or Cy5TM -
conjugated donkey secondary antibodies (Jackson ImmunoResearch Laboratories, 
Inc., West Grove, PA) at a dilution of 1:2,000 with 2.5% horse serum in PHEM 
buffer at room temperature for 40 min. Cells were then incubated with 500 ng/ml 
DAPI (Santa Cruz Biotechnology, Inc.) to identify the nuclei. ProLong® Gold 
antifade reagent (Invitrogen) was used for mounting. Images were acquired on a 
confocal microscope (LSM 510 META, Carl Zeiss GmbH, Jena, Germany) with a 
Plan-NeoFluar ×40/1.3 oil DIC objective (optical section ~1 μm). To avoid cross-
talk, DAPI, EGFP, Cy3, and Cy5 fluorescence was detected sequentially using 
the 405 nm laser in combination with the BP420-480 nm filter, the 488 nm laser 
with the BP505-550 nm filter, the 543 nm laser with the BP561-646 nm filter, 
and the 633 nm laser with the BP646-732 nm filter, respectively.  
 
2.08. Luciferase reporter assay  
 
HeLa-shLuc or HeLa-shRHAU cells, pool of four different clones, were seeded in 
12-well plates (1×105 cells per well) with or without doxycycline (1 μg/ml). 24 h 
later, cells were transfected with 250 ng of pGL2-promoter (Promega Co., 
Madison, WI), a firefly luciferase-expressing plasmid, together with 1 ng of pRL-
TK (for renilla luciferase expressin as internal control) using FuGENE6. 48 h 
after transfection, cell lysates were prepared and luciferase expression was 
measured according to the given protocol (Dual-Luciferase Reporter Assay 
System, Promega). Firefly luciferase activity was normalized by renilla luciferase 
activity. Fold activation was derived from the normalization with dox- samples.  
 
2.09. GeneChip microarrays and the analysis of RNA half-lives 
 
HeLa-shLuc and HeLa-shRHAU cells were treated with doxycycline (1 μg/ml) for 
6 days. On the 4th day of dox-treatment, four clones of each cell line were pooled 
and a total of 2×106 cells were reseeded in 10 cm dishes. For the starvation 
experiment, the medium was replaced with serum-free DMEM on the 5th day, 24 
h before the collection of RNA. The ActD-chase experiment was done on the 6th 
day of doxycycline treatment. 5 μg/ml ActD was added to the medium, and total 
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RNA was collected at 0, 30, 60, 90, and 120 min after the addition of ActD. 
Samples for time 0, representing the total amount of RNA collected from cells 
cultured in FCS-containing or starvation conditions were analyzed in triplicate, 
whereas ActD-treated samples for the mRNA decay study were analyzed in 
duplicate. Total RNA was isolated using the RNeasy kit from QIAGEN 
(Hombrechtikon, Switzerland).  
Total RNA (5 μg) from each replicate was reverse transcribed and labeled using 
the Affymetrix 1-cycle labeling kit according to manufacturer’s instructions. 
Biotinylated cRNA (20 μg) was fragmented by heating with magnesium (as per 
Affymetrix’s instructions) and 15 μg of this fragmented cRNA was hybridized to 
Human U133 plus 2.0 GeneChipsTM (Affymetrix, Santa Clara, CA). GC-RMA 
expression values and detection P-values were estimated using Refiner 4.0 from 
Genedata AG (Basel, Switzerland). Data analysis was performed using Analyst 
4.0 from Genedata AG. The chip distributions were standardized by quantile 
normalization and they were scaled to make the median expression value, of 
genes with a detection P-value < 0.04, equal to 500. For the analysis of steady-
state RNA levels, genes were required to have a detection P-value of less than 
0.04 (Affymetrix default) in at least two replicates of at least one condition. The 
objective was to exclude genes that are not expressed in any condition. They were 
then subjected to a student t-test (P<0.05) and have a median fold change of 1.5 
or 2 greater between samples dox+ and dox- or with and without starvation. 
Multiple testing errors were dealt with using a Benjamini and Hochberg false 
discovery correction. 
To obtain mRNA half-lives, we used expression levels from the Affymetrix 
expression arrays at the start of the experiment (three biological replicates, “time 
0”) and at four successive timepoints (30, 60, 90, and 120 minutes, two biological 
replicates each). First, mRNAs with long half-lives were identified, defined by 
expression levels that decreased less than 13%  (= 1 - 2^(-120/600)) in the course 
of 120 minutes, corresponding to half-lives of 600 minutes or more. Half-lives and 
the corresponding standard errors of the remaining mRNAs were estimated by 
fitting the time-course expression data to an exponential decay function N(t) = N0 
× 2^( -t / t1/2 ), where N(t) and N0 correspond to the expression levels at 
timepoints t and zero, respectively, and t1/2 to the half-life, using the nonlinear 
least squares method as implemented in the R statistical program (www.r-
project.org). Differences in half-lives were identified based on estimated half-lives 
and standard errors using the method described by Payton et al. (Payton et al. 
2003). Half-lives with non-overlapping 88% confidence intervals were considered 
significantly different at a P value of 0.05. 
For the general data analysis, the significance of the overlap between two sets of 
genes was calculated using the hypergeometric distribution as implemented in 
the R statistical program, which was also used to generate density plots of half-
lives. 
To find ARE-containing mRNAs, we used the human AU-rich element-containing 
mRNA database ARED (http://rc.kfshrc.edu.sa/ARED/). For the analysis of genes 
containing G4 structure in the promoter, the human promoters (defined as a 
sequence of 1000 nucleotides upstream of annotated transcripts that overlap 
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Affymetrix probesets) were obtained from Ensembl (www.ensembl.org, release 
44) using a Perl script and the Ensembl Perl API (Curwen et al. 2004). Sequences 
were then scanned for the presence of G4 sequence using quadparser (Huppert 
and Balasubramanian 2005) with standard parameters. 
The entire set of microarray data is in GEO (Gene Expression Omnibus) with 
accession number GSE8192. The list of RHAU-regulated probe sets at steady-
state mRNA level, by mRNA stability, and the list of starvation-sensitive genes 
are shown in Appendix II, III, and IV, respectively.  
 
2.10. Cell growth and viability  
 
HeLa-shLuc or HeLa-shRHAU cells, pool of four different clones, were cultured 
with or without doxycycline for 5 days. For the growth analysis in FCS-
containing condition, 1.5×105 cells per well were seeded in 12-well plates and 
viable cell numbers were obtained every 24 h using the automated cell counter 
ViCellTM (Beckman Coulter, Inc., Fullerton, CA). For the starvation experiment, 
3×105 cells per well were seeded in 12-well plates. 24 h later, the medium was 
replaced with serum-free medium and viable cell numbers and cell viability 
values were obtained every 24 h using ViCellTM. Microscopic images showing cell 
morphology were captured by a phase contrast microscope. To count apoptotic 
cells, AnnexinV-positive cells were detected by FACS using anti-AnnexinV-APC 
antibody, according to a manufacturer’s instruction (BD Biosciences Pharmingen). 
To detect apoptotic marker proteins, starved cells were collected for Western 
blotting and stained by anti-cleaved caspase3 and anti-cleaved PARP antibodies.  
 
2.11. Nuclear run-on assay  
 
HeLa-shRHAU cells (clone 25) were treated for 6 days with doxycycline and then 
nuclear fractions were prepared as described (Medcalf et al. 1988). In vitro 
transcription was performed in 200 µl of run-on reaction buffer (5 mM Tris-HCl, 
pH 8.0, 2.5 mM MgCl2, 150 mM KCl) containing cold ATP, CTP, GTP (5 mM each) 
and [γ-32P] UTP (100 µCi) and incubated at 30ºC for 30 min. RNA was purified 
and hybridized with specific cDNA (1 µg) immobilized on a positively charged 
nylon membrane for 3 days at 42°C. Hybridization signals were visualized and 
quantified using a Phosphoimager, and analyzed using Molecular Dynamics 
(version 5.2).  
 
2.12. Real time PCR  
 
First-strand cDNA was synthesized from total RNA (1 µg) isolated from HeLa-
shRHAU cells transfected with Flag-RHAUsm or empty vector (pBR-322), using 
the QuantiTect Reverse Transcription kit (QIAGEN) according to the 
manufacturer’s instructions. 1 µl of ten-times diluted RT reaction mixture was 
used to perform PCR with specific primer pairs (shown in APPENDIX I) 
corresponding to a particular gene of interest. Real-time PCR was performed 
using the QuantiTect SYBR Green PCR kit (QIAGEN) and the ABI PRISM 7000 
sequence detector (Applied Biosystems, Foster City, CA) according to the 
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manufacturers’ instructions. We used NDUFA12 (NADH dehydrogenase 
(ubiquinone) 1 alpha subcomplex, 12) for the normalization since expression of 
this gene was not altered in any samples analyzed by the microarray.  
 
2.13. Tumor generation in nude mice 
 
HeLa-TR-shRHAU1 or HeLa-TR-shRHAU2 cells were cultured with 1 μg/ml 
doxycycline for two days. Viable cells were counted and suspended in PBS (2×107 
cells /ml). CD1 female nude mice (Charles River Laboratories, Inc., Sulzfeld 
Germany) were fed with water containing or not containing doxycycline (1mg/ml) 
two days prior to injection. HeLa cells in PBS (two million cells per injection) 
were subcutaneously injected into the right and left flanks of the nude mice. Once 
a tumor was detected, transcutaneous caliper measurements were used to 
measure the long and short dimensions of the tumor. Tumor volume was 
calculated on the assumption of an ellipsoidal volume, which was observed to be 
the predominant shape of the tumors. The tumor volume in milliliters was 
calculated according to the following formula, V=4/3 ab2, where V represents 
volume and a and b represent the semiaxial dimensions.  
 
2.14. GST-RHAU pull-down assay   
 
Plasmids, pGEX-RHAU(1-200aa) or pGEX-2T, were transformed into Escherichia 
coli BL21 cells. Glutathion S-transferase (GST) fusion proteins were produced in 
the transformed BL21 cells and purified using glutathione sepharose 4B beads 
(GE healthcare). About 40 μg of purified GST proteins were incubated with 4 mg 
of HeLa nuclear or cytoplasmic S100 extracts in Buffer D (10 mM Hepes-KOH, 
pH 7.9, 3 mM MgOAc, 10% glycerol, 0.1 mM EDTA, 0.1 mM PMSF and 0.5 mM 
DTT) for two hours at 4 °C. Unbound proteins were removed by washing with 
Buffer D. Beads were boiled for 5 min in SDS-PAGE sample buffer and eluted 
proteins were analyzed in 10 % SDS-PAGE. Gels were stained with Coomassie 
blue. Proteins specifically interacting with GST-RHAU N-ter were identified by 
LC-MSMS. 
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Section 3  -  Results 
 
 
 
3.01. Possible roles of RHAU in the nucleus.   
 
3.01.01. RHAU is mainly localized in the nucleus and tightly associated with 
RNA.  
Previous studies have shown that 
exogenously expressed HA-
RHAU is predominantly localized 
in the nucleus in HeLa cells 
(Tran et al. 2004). To investigate 
endogenous RHAU distribution, 
we performed cellular 
fractionation followed by 
Western blotting. Cells were first 
treated with detergent (0.5% 
Triton-X100) in CSK buffer, 
which permeabilized the plasma 
membranes. This buffer extracts 
cytoplasmic proteins from the cell 
and the supernatant, thus, 
contains cytoplasmic proteins 
such as β-tubulin and GAPDH, 
and the pellet contains nuclear 
proteins such as hnRNPC1/C2 
and histone 3, as well as the 
transcription factor Oct1 and the 
splicing factor SC35 (Figure 3, 
lanes 1 and 2). RHAU was found 
in both the cytoplasmic and 
nuclear fractions, being more 
abundant in the latter. Nuclear 
fractions thus obtained were further fractionated using 0.25 M ammonium 
sulfate buffer to extract soluble proteins such as protein kinase ERK1 and 
nuclear export factor CRM1, leaving insoluble fractions that have strong 
interactions with nuclear structures, such as chromatin and ribonuclear proteins 
(RNPs) represented by histone3, hnRNPC1/C2, Oct1, and SC35 (Fey et al. 1986). 
A small but significant portion of endogenous RHAU was present in the nuclear 
insoluble fractions, with a distribution pattern similar to NF90, a dsRNA and 
ARE-binding protein. In contrast, large amounts of nuclear histone deacetylase 1 
(HDAC1), telomere-binding protein Ku80, and RHA were extracted with 
ammonium sulfate buffer (compare lanes 2, 3, and 4 in Figure 3). These results 
indicate that RHAU is a nuclear protein associated with nuclear structure with a 
similar or stronger affinity than other RNA-/ DNA-binding proteins.  
 
 
 
Figure 3. Cell fractionation using HeLa cells. Total HeLa 
cells were fractionated using CSK buffer to separate 
cytoplasmic (Cyt) and nuclear (Nuc) fractions. Nuclear 
fractions were further fractionated using an ammonium sulfate 
buffer to separate nuclear soluble (sup) and insoluble (pt) 
fractions. Each fraction corresponding to the equivalent cell 
numbers was analyzed by Western blotting using the 
antibodies indicated.  
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In parallel, a similar analysis was done using the exogenously expressed EGFP-
tagged RHAU. While mouse monoclonal and rabbit polyclonal antibodies against 
RHAU used in this work efficiently detected RHAU protein by Western blotting, 
they were unsuitable for detecting endogenous RHAU by immunocytochemistry. 
Therefore, to further investigate the cellular localization of RHAU, EGFP-tagged 
RHAU expression vectors were prepared and transiently transfected into HeLa 
cells. If EGFP-RHAU is tightly associated with nuclear structures, it should 
remain there even when nuclear membrane is permeabilized. To see if this was 
the case, cells were treated with 0.1% Triton X-100, washed out, then fixed with 
paraformaldehyde.  Soluble nuclear protein such as EGFP was completely 
released from the nucleus in this condition (Figure 4B, EGFP, compare lanes fix 
and Triton). In contrast, significant level of fluorescence was still detected in the 
cells transfected with EGFP-RHAU albeit that the intensity was decreased 
(Figure 4A). In greater than 200 cells counted, 37.2 % of transfected cells showed 
detectable EGFP-signal after the Triton-permeabilization (17.7% cells out of 
47.6% transfected cells). Further DNase treatment to the permeabilized cells did 
not change proportion of EGFP-RHAU-positive cells, whereas almost no cells 
showed the signal after the RNase treatment (Figure 4, compare Triton-
permeabilized and DNase, RNase). The results of biochemical fractionation and 
the in situ extraction suggested that RHAU tightly associated with higher 
nuclear structures via RNA.  
 
 
 
Figure 4. In situ extraction of EGFP-RHAU. (A) EGFP fluorescence images of cells transfected with EGFP-
RHAU. Cells were transiently transfected with EGFP-RHAU and either fixed or permeabilized with 0.1 % Triton-
X100. The permeabilized cells were further treated with DNase I (100 U/ml) with RNAsin or mixture of RNase A 
(20 μg/ml) and RNase T1 (100 U/ml), then fixed. (B) Cells showing significant EGFP-fluorescence were counted 
in greater than 200 cells in images taken from microscope. Average of two independent experiments is shown. 
Error bar, SEM.  
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3.01.02. Nuclear speckles and nucleolar cap-localization induced by 
transcriptional arrest.   
 
The distribution of nuclear RHAU was further examined using EGFP-RHAU 
constructs. To avoid an artifact caused by terminal attachment of EGFP to 
RHAU, EGFP was tagged at either the N-terminal (EGFP-RHAU) or the C-
terminal (RHAU-EGFP). Although the expression levels of differently tagged 
RHAU was about threefold different (Western blotting, Figure 5A, compare lanes 
3 and 4), both proteins showed very similar distribution patterns. They were 
localized mainly in the nucleus excluding the nucleoli, with much lower 
expression in the cytoplasm. We found that RHAU was concentrated in nuclear 
speckles enriched with splicing factors and mRNAs (marked with splicing factor 
SC35) (Lamond and Spector 2003; Hall et al. 2006) but less abundant in 
heterochromatin (marked with H3-K9 trimethylation), supporting the idea that 
RHAU is closely associated with RNA but not compacted DNA (Figure 5B-a, b). 
 
Therefore, we have examined whether RNA synthesis is linked to the specific 
nuclear localization of RHAU. Cells were treated with ActD, which intercalates 
into DNA and inhibits transcription by all types of RNA polymerase. In this 
condition, RHAU was no longer enriched in the nuclear speckles but formed 
prominent structures around the nucleoli. This structure was located close to but 
completely excluded from heterochromatin, as visualized by the antibody against 
H3-K9 trimethylation (Figure 5B-c, d). Time-course analysis showed that RHAU-
containing cap-like structures became visible 1 h after the addition of ActD and 
enlarged subsequently. After 5 h, they completely occupied the nucleoli, but by 
then most cells were undergoing apoptosis (Figure 6). Treatment with DRB, an 
RNA polymerase II-specific inhibitor, exhibited a similar but milder effect on 
RHAU localization than ActD treatment; less RHAU was found around nucleoli 
and a significant amount was still concentrated in nuclear speckles (see Figure 7).  
 
An ATPase-deficient mutant was also examined to see whether RHAU ATPase 
activity influences its cellular localization. EGFP-RHAU-E335A has an amino 
acid replacement at motif II of the conserved helicase domain from DEIH to 
DAIH and this mutation has been shown to cause a complete loss of RHAU 
ATPase activity in vitro (Tran et al. 2004). The ATPase-deficient mutant was 
localized only in the cytoplasm and its distribution was not altered by inhibition 
of transcription, suggesting that ATPase activity is necessary for the nuclear 
localization of RHAU (Figure 5C). As a control, EGFP alone was expressed and 
was seen to be distributed uniformly in the nucleoplasm under normal conditions. 
EGFP did not form cap-like structures upon treatment with any transcriptional 
inhibitors (Figure 5D).  
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Figure 5. RHAU is enriched in the nucleus. (A) Western blotting showing EGFP-tagged RHAU. HeLa cells were 
transfected with EGFP-tagged RHAU (EGFP-RHAU or RHAU-EGFP), ATPase-deficient RHAU mutants (EGFP-
E335A or E335A-EGFP) or EGFP. Total cell lysates were analyzed by Western blotting using the antibodies 
indicated. (B) Immunofluorescence images of EGFP-expressing cells. HeLa cells were transiently transfected with 
vectors expressing EGFP-tagged proteins. For ActD treatment, the drug (5 μg/ml) was added to the culture 2 h prior 
to fixation. Cells were multiply stained with anti-SC35 antibody (nuclear speckles; in red), anti-H3 K9-trimethylation 
antibody (heterochromatin; in blue), and DAPI (DNA; in white). The merging of three colors for EGFP, SC35, and 
H3-K9triMet is shown. For cells transfected with RHAU-EGFP and E335A-EGFP, only merged images are shown. 
Scale bar: 5 μm. 
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3.01.03 Transcription-dependent localization of RHAU in the nucleolar caps with 
DEAD-box helicases p68 and p72. 
 
The ActD-induced structures of RHAU around nucleoli resembled previously 
reported nucleolar caps around nucleoli in mammalian cells upon transcriptional 
arrest (Shav-Tal et al. 2005). In this report, DEAD-box RNA helicase p68 was 
found to be localized in nucleolar caps when cells were treated with ActD. To test 
whether RHAU is co-localized with p68 and its dimmer partner, p72, in the 
nucleolar caps, HA-tagged p68 or p72 were co-transfected with EGFP-RHAU and 
cells were stained with anti-HA and anti-SC35 antibodies. Under normal culture 
conditions, HA-p68 and HA-p72 were both concentrated in nuclear speckles as 
reported previously (Saitoh et al. 2004; Enukashvily et al. 2005), where EGFP-
RHAU was also present (Figure 7 a, d: Co-localization of the three proteins 
appears as white areas in merged pictures resulting from a mix of red, blue, and 
green.). In transcription-arrested cells, p68 formed nucleolar caps and this was 
more marked with DRB than ActD (Figure 7 b, c). In contrast, p72 was more 
sensitive to ActD, forming a ring structure around nucleoli. In this situation of 
p72 overexpression, the localization of RHAU changed to a ring structure within 
p72 and no nucleoplasmic distribution was observed (Figure 7 e, f). Since single 
transfection of EGFP-RHAU or co-transfection with HA-p68 did not show such a 
remarkable structure, it seems that p72 recruited RHAU into such a structure 
around the nucleoli. In either case, RHAU was co-localized with p68 and p72 at 
the periphery of nucleolar caps, indicating that the structure formed by EGFP-
RHAU was a part of the previously characterized nucleolar caps.  
 
 
 
 
Figure 6. Nucleolar cap formation of EGFP-RHAU upon ActD treatment. HeLa cells were transiently 
transfected with EGFP-RHAU and treated with ActD (5 μg/ml) for the indicated time (0 - 5hr) prior to fixation. 
Nucleolar caps are indicated by arrow heads. Scale bar: 5 μm. 
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Figure 7. RHAU is co-localized with p68 and p72 in nucleolar caps upon transcriptional inhibition. (A) 
Immunofluorescence images of EGFP-expressing cells. ActD (5 μg/ml) or DRB (25 μg/ml) was added to the 
culture 2 h prior to fixation. Cells were stained with anti-HA antibody (in red), anti-SC35 antibody (in blue), and 
DAPI (in white). The merging of three colors for EGFP, HA, and SC35 is shown. Scale bar: 5 μm.  
 
 
 
 
3.01.04 Interaction of RHAU with regulators of transcription.  
 
To see whether RHAU interacts with p68 and p72, we transiently transfected 
Flag-RHAU together with HA-p68 or HA-p72 into HeLa cells and performed 
immunoprecipitation using anti-Flag antibody. HA-p68 and HA-p72 were co-
precipitated with Flag-RHAU, indicating that RHAU interacts with p68 and p72 
in cells (Figure 8A). Since p68 and p72 have been characterized as regulators of 
transcription, interaction between RHAU and these proteins suggest possible 
involvement of RHAU in transcriptional regulation. To see whether RHAU 
interacts with other known transcription regulators, the immunopreciptation was 
performed with HDAC1 and 3. Histone deacetylases (HDACs) are general 
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transcription repressors and it has been reported that p68 and p72 associates 
with HDAC1, showing that these helicases repress transcription in some contexts 
(Wilson et al. 2004). We could detect the co-precipitation of RHAU when HDAC1 
and HDAC3 were immunoprecipitated, suggesting that RHAU could be a part of 
transcriptional repression complex (Figure 8B). Since the addition of RNases into 
lysates abolished any of these interaction, RHAU likely associates with them via 
RNA.  
 
 
 
 
Figure 8.  Interactions between RHAU and p68, p72, HDACs. (A) pcDNA3-Flag (Vec) or Flag-RHAU was co-
transfected with either HA-p68 or HA-p72 into HeLa cells. Flag-RHAU was immunoprecipitated with anti-Flag 
and co-precipitated HA-p68 or HA-p72 proteins were visualized by Western blottings using anti-HA antibody. *; 
non-specific band. (B) pcDNA3-Flag (Vec), Flag-HDAC1, or Flag-HDAC3 was co-transfected with HA-RHAU 
into HeLa cells. Flag-HDAC was immunoprecipitated with anti-Flag and co-precipitated HA-RHAU was 
visualized by Western blottings using anti-HA antibody.  5% of input is also shown. 
 
 
 
 
 
3.01.05 N-terminal domain of RHAU is responsible for the nuclear and nucleolar 
caps localization.  
 
RHAU consists of a central helicase core region and N-terminal and C-terminal 
extended domains (Figure 9A). The beginning of the N-terminus contains a 
glycine-rich motif and the end of the helicase core region possesses a putative 
nuclear export signal that is enriched with leucine. We made truncated mutants 
of RHAU in each domain to characterize essential domains of RHAU for the 
nuclear location. Deletion mutants of RHAU tagged with EGFP showed that the 
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200 N-terminal amino acids were required for the nuclear localization because 
the deletion of those residues showed complete cytoplasmic localization of RHAU 
(Figure 9B-d, e, f). In contrast, the N-terminal domain was sufficient for 
localization in the nucleus, and it was concentrated in the nuclear speckles 
(Figure 9B-a). Upon inhibition of transcription by ActD, all truncated mutants 
which would normally go to the nucleus showed nucleolar caps (Figure 9B-g, h, i), 
indicating that import to the nucleus is sufficient for the formation of these caps. 
 
 
 
 
 
 
 
 
Figure 9. N-terminal domain of RHAU is responsible for the nuclear and nucleolar caps localization. 
Differently truncated forms of RHAU were fused with EGFP at their N-termini. Each construct was transfected 
into HeLa cells. ActD (5 μg/ml) was added 2 h prior to fixation. EGFP-fluorescence was captured and is shown in 
white. (A) A schematic representation of various EGFP-RHAU constructs with the summary of results of their 
cellular localization. (B) Fluorescent images of cells transfected with the above-shown EGFP-RHAU constructs 
before and after ActD treatment. Scale bar: 5 μm. 
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3.02. Microarray analysis using RHAU knockdown cells.  
 
The intracellular localization studies have shown that: [1] RHAU is much more 
abundant in the nucleus than in cytoplasm; [2] in the nucleus, RHAU is 
concentrated in RNA-rich nuclear speckles; [3] RNA-synthesis influences the 
distribution pattern of RHAU in the nucleus. These results prompted us to 
consider the possibility that RHAU influences some RNA metabolic pathways in 
the nucleus and, therefore, it may affect global gene expression either directly or 
indirectly. To test this hypothesis and to identify the possible genes affected, we 
performed Affymetrix microarray analysis using RHAU-depleted cells.  
 
3.02.01. Inducible RHAU-knockdown HeLa cell-line.  
 
To establish HeLa-T-REx-derived cell lines in which RHAU-specific hairpin RNA 
(shRNA) could be induced by doxycycline (van de Wetering et al. 2003), plasmids 
expressing shRNAs to target RHAU (shRHAU) and luciferase (shLuc) as a 
control under the control of the Tet repressor were stably transfected and zeocin-
resistant clones were picked. To reduce clone-specific effects, we pooled four 
independent clones from each shRNA-transfection. Such a pool was then treated 
as one experimental replicate in the analysis. Western blots showed that RHAU 
was reduced in all the clones down to 30% of that found in the controls after 6 
days of doxycycline treatment (Figure 10A). In time-course experiments, maximal 
downregulation was observed after a 6-day doxycycline treatment and, therefore, 
a 6-day treatment was used in all subsequent experiments. Expression of shLuc 
in control cells was confirmed from the downregulation of luciferase activity by 
transient transfection assays (Figure 10B).  
 
 
 
 
Figure 10. RHAU knockdown in HeLa cells by RHAU-specific shRNA expression. (A) Four independent 
clones derived from HeLa-shLuc or HeLa-shRHAU cells were pooled and treated or not treated with doxycycline 
(1 μg/ml) to induce shRNA for 6 days. RHAU knockdown in pooled and four individual HeLa-shRHAU clones 
was assessed by Western blotting using anti-RHAU antibody. Pool, pool of four individual clones; shRHAU 
clones, individual clones (B) HeLa-shLuc or HeLa-shRHAU cells were transiently transfected with firefly 
luciferase-expressing vector (pGL2-promoter) with or without co-treatment with doxycycline (1 μg/ml). Cells were 
collected 48 h after transfection. Firefly luciferase activity was normalized by renilla luciferase that was co-
transfected as an internal control. Error bar, SEM of three replicates.  
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3.02.02. DNA microarray to measure steady-state mRNA and mRNA half-life.  
 
RHAU was originally characterized as a destabilizer of uPA mRNA. As the 
steady-state level of mRNA reflects both its de novo synthesis and its degradation, 
we examined both steady-state levels of mRNAs and their half-lives by the 
microarray using RHAU knockdown cell lines. After complete knockdown of 
RHAU, cellular transcription was inhibited by ActD and total RNAs were 
collected every 30 min up to 120 min to determine the half-lives (see 
experimental procedure in Figure 11). The data from our microarrays showed 
that the expression of RHAU itself was successfully reduced to about 20% in 
doxycycline-treated (dox+) cells (Figure 11A). Acceleration of RHAU mRNA decay 
by shRNA-mediated mRNA degradation was also confirmed with a significant 
change in its half-life (Figure 11B). Thus, it was shown that microarray 
experiments could successfully detect changes in mRNA stability. 
 
 
 
 
Figure 11. Microarray to measure both steady-state mRNA level and mRNA half-life. The scheme of 
microarray experiment is described. (A, B) Expression data of RHAU (Affymetrix name 223138_s_at) obtained 
from microarray analysis was plotted. Error bar, SEM of three or two replicates from microarray. (A) Steady-state 
mRNA level. (B) Decay of RHAU mRNA, which was accelerated by shRNA-mediated mRNA degradation. 
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Half-lives and the corresponding standard errors of every mRNA was estimated 
by fitting the time-course expression data of five time points to an exponential 
decay function using the nonlinear least squares method (See detail analysis in 
Material and Methods). We could confirm that ActD suppressed general 
transcription in our experiment since global decrease of mRNA levels in the ActD 
chase was detected by the microarray (Figure 12).  
 
 
 
 
 
 
Figure 12. Box plots of mRNA levels at five time points. For each time point, a box plot of the observed 
expression levels is shown. The black line indicates the median, lower and upper box limits the first and third 
quartiles, respectively, and the whiskers show the total spread. Values further away than 1.5 times the interquartile 
range from the box were omitted as outliers. The difference of medians is significantly different at P ≤ 0.05 if the 
notches around the medians of two box plots do not overlap. 
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3.02.03. Differences in steady-state levels after RHAU knockdown are not 
correlated to their half-lives.   
 
To analyze microarray data, we first picked mRNAs showing significant 
differences in steady-state levels (time 0 of ActD treatment) in HeLa-shRHAU 
cells between doxycycline non-treated (dox-) and treated (dox+) conditions. As 
summarized in Table 1, 125 mRNAs showed more than a two-fold up- or down-
regulation in RHAU-knockdown cells (dox+) compared with dox- cells. In 
contrast, only two mRNAs showed a twofold difference in expression after 
doxycycline treatment in control HeLa-shLuc cells, indicating little effect of 
doxycycline on global gene expression (See gene lists in Appendix II).  
 
 
 
 
 
TABLE 1.  Comparison of probe sets with significantly altered steady-state 
levels in HeLa-shRHAU cells and other specific probe sets 
    
   DmRNA half-life 
  
ASteady-state  
BARE CG4 decrease increase 
>1.5 fold up 428  ***109 n.s 142 ***73 n.s 0 
 down 474  **52 **191 n.s 6 **17 
> two-folds up 58  **13 n.s 22 **13 n.s 0 
 down 67  n.s 5 n.s 28 n.s 2 n.s 2 
 
Number of common probe sets between the sets that significantly increase or decrease their 
expression values in HeLa-shRHAU cells between dox- and dox+ (defined by P<0.05 and a 
minimal fold change, see Materials and Methods) and sets defined by additional 
characteristics are shown. The significance of the overlap is indicated as n.s.; not significant, 
*; P<0.01, **; P<0.001, ***; P < 2e-16, calculated using the hypergeometric distribution, 
with n corresponding to the total number of genes in the column-set and N indicating the total 
number of genes analyzed in both column- and row-sets. (A) Fold difference of total mRNA 
amount in HeLa-shRHAU cells between dox- and dox+ (P<0.05). N=30,599. Up, up-
regulated in dox+; down, down-regulated in dox+. (B) Number of ARE-containing probe sets 
found in ARED (http://rc.kfshrc.edu.sa/ARED/).  N=30,599, n=1,530; n was estimated under 
the assumption that the fraction of ARE-containing genes in the published screen (5%, 
(Bakheet et al. 2006)) is the same as the fraction of ARE-containing genes of all genes 
represented on the Affymetrix microarray. (C) Number of putative G4-sequence containing 
probe sets in the promoters (in 1 kb upstream from transcription starting sites) found by 
quadparser (Huppert and Balasubramanian 2005) with standard parameters. N=30,599, 
n=13,066; n was estimated under the assumption that the fraction of genes with G4-containing 
promoters in the published screen (42.7%, (Huppert and Balasubramanian 2005)) is the same 
as the fraction of genes with G4-containing promoters of all genes represented on the 
Affymetrix microarray. (D) Number of probe sets showing different half-lives (P< 0.05) 
between dox- and dox+ samples. Decrease or Increase, decreased or increased half-life in 
dox+. N=6,973, ndecrease=203, nincrease=99.   
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Correlation between the steady-state differences and their half-lives were then 
examined. Based on the half-life profiles, up- or down-regulated mRNAs in 
RHAU-knockdown were assigned to three groups (Figure 13). The major group 
(Group 1) includes those mRNAs whose steady-state levels were altered without 
changes in half-life, as represented by DAPK1 and CLUAP1 mRNAs (Figure 14). 
Groups 2 shows opposing correlation between steady-state level and mRNA decay, 
namely up-regulated steady-state levels with decreased half-lives or down-
regulated steady-state levels with increased half-life (represented by SPRED1, 
Figure 14). Group 3 contains mRNAs whose steady-state levels were correlated 
with the mRNA decay rate as represented by CDKN1C, which showed decreased 
steady-state level and decreased mRNA half-life (Figure 14). Except for Group 3, 
involvement of the mRNA decay mechanism is unlikely, since changes in mRNA 
half-lives did not reflect steady-state mRNA levels. This is true for 99% of 
mRNAs whose steady state levels were affected by RHAU knockdown. These 
results suggest that the influence of RHAU on global gene expression is in 
general not through mRNA decay but rather through steps in the nucleus 
including transcription.  
 
Among the mRNAs whose stability was up-regulated by RHAU knockdown, we 
collected a significant number of ARE-containing mRNAs that were found in the 
ARE-database, ARED (Bakheet et al. 2006) (Table 1B, see also Appendix II). 
However, the existence of ARE was not necessarily correlated to the 
misregulation of their half-lives, since the half-lives of the majority of ARE-
containing mRNAs did not change in RHAU knockdown (5 out of 18 mRNAs 
showed changes of half-lives). This indicated that the effect of RHAU on steady-
state mRNA level was not restricted to the ARE-mediated mRNA decay. We also 
analyzed whether those RHAU-regulated genes contained one or more G4 DNA 
structures in their promoters. According to bioinformatics analysis, about 40% of 
human promoters contain putative G4 sequences (Huppert and 
Balasubramanian 2005). In the down-regulated genes in RHAU knockdown, but 
not in the up-regulated mRNAs, we saw a slight enrichment of G4 sequences 
(53.5%) in their promoters, which was statistically significant (P<0.001) (Table 
1C). Thus, they are candidate target genes of the G4-resolvase RHAU, as RHAU 
resolves G4 DNA in their promoters, which activates transcription. However, the 
effect of RHAU knockdown on the abundance of G4 DNA in promoters was mild, 
and in fact no significant enrichment of G4 sequences was seen in 2-fold down-
regulated mRNAs, suggesting that there could be another mechanism affecting 
mRNA steady-state levels in RHAU knockdown cells. 
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Figure 13. The relationship of steady-state difference and mRNA half-lives in RHAU-knock down cells.  
Three groups of steady-state different mRNAs and percentage of those mRNAs in up- or down- regulation is shown.  
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Figure 14. mRNAs regulated by RHAU. Expression values were obtained from microarray analysis. mRNAs 
whose expression levels were significantly affected after RHAU knockdown induced by doxycycline were selected 
and are represented here by six different mRNAs: DAPK1 (Affymetrix probe name: 203139_at), SPRED1 
(226837_at), CLUAP1 (204576_s_at), CDKN1C (213348_at). The left panel shows steady-state levels of mRNAs 
normalized over the sample of dox- in cells. The right panel shows the mRNA decay curve. mRNA expression was 
normalized over time 0 as 100%.  
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3.02.04. Influence of RHAU on mRNA half-life.    
 
In the analysis of the mRNA decay rate, we found 99 mRNAs were significantly 
stabilized and 200 mRNAs were destabilized in knockdown although, 
surprisingly, the steady-state levels of the majority of these mRNAs were not 
significantly affected (Table 2, see also gene lists in Appendix III). The density 
plot of their half-lives is shown in Figure 15A. The y-axis shows the density of 
genes in each half-life shown on the x-axis. In contrast to control shLuc cells 
which showed almost no difference between dox- and dox+, shRHAU cells showed 
a greater difference as overall distribution was shifted towards longer half-life in 
dox+, suggesting that RHAU tends to destabilize mRNAs as it was previously 
characterized. However, when we looked individual mRNAs, there were 
significantly more numbers of mRNAs showing decreased half-life in RHAU 
knockdown, suggesting that RHAU also stabilizes other mRNAs (Table 2). When 
we look at half-lives of mRNAs showing significant differenced on steady-state 
levels, mRNAs whose steady-state levels were down-regulated did not show any 
significant half-life differences following RHAU knockdown. In contrast, half-
lives in up-regulated mRNAs became significantly shorter after RHAU 
knockdown (in red, compare dox+ and dox-). Although this tendency indicates 
that up-regulation of those mRNAs was attributable not to the increase in their 
half-lives but rather to enhanced transcription, it suggests that regulation of 
mRNA stability also exists at the same time, perhaps to compensate the 
increased transcription rate.   
 
 
 
 
TABLE 2. Number of probe sets with significantly altered mRNA half-life in 
HeLa-shRHAU or HeLa-shLuc cells treated with dox. 
         
  sig. decrease  sig. increase 
  AP<0.02 BP<0.05
CSteady-
state 
 AP<0.02 BP<0.05 
CSteady-
state 
shRHAUa  93 203 15 24 99 2
shLucb  3 18 1 5 28 0
 
(A and B) Number of probe sets showing statistically significant (P<0.02 or P<0.05) decrease or increase on their 
half-life between dox- and dox+ in HeLa-shRHAU or HeLa-shLuc cells. (C) Number of common probe sets 
between the sets of half-life differences (p<0.05, the number showed by B) and the sets that show significantly 
different steady-state level between dox- and dox+ (defined by P<0.05 and a minimal two-fold difference). a, 
n=5613; b, n=17221. 
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Figure 15. Distribution of RHAU-regulated mRNA half-lives.  (A) Density plot of mRNA half-lives in shLuc 
cells (n=17221) or in shRHAU cells (n=5613). (B) Density plot of mRNA half-lives for gene sets whose steady-
state levels were upregulated (red, n=58) or down-regulated (green, n=67) by RHAU knockdown in shRHAU 
cells. 
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3.02.05. Change in mRNA level in RHAU-knockdown cells can be rescued by 
exogenous RHAU expression.   
 
To validate the microarray data, expression of several mRNAs was assessed by 
real-time PCR. We also examined whether the effect of RHAU knockdown can be 
reversed by exogenous expression of Flag-tagged RHAUsm. This expression 
vector harbored a silent mutation at the target site of shRNA (Flag-RHAUsm) 
allowing it to escape siRNA-mediated downregulation. Western blot analysis 
showed that exogenous Flag-RHAUsm was expressed at a level similar to 
endogenous RHAU, indicating that Flag-RHAUsm expression can restore RHAU 
in doxycycline-treated cells (Figure 16A). As shown in Figure16B, real-time PCR 
is in agreement with the microarray analysis (compare dox- and dox+; lanes 1 
and 2) and expression of Flag-RHAUsm rescued the effect of RHAU knockdown 
on many target mRNAs (dox+ with exogenous expression, in lane 3). Failure to 
reverse the effect of RHAU knockdown on some mRNAs suggests that these 
mRNAs are not direct targets of RHAU.  
 
 
 
Figure 16. Rescue expression of RHAU by transient transfection of the silent RHAU mutant. The empty 
vector (pBR-322) or Flag-RHAUsm (silent mutation) was transiently transfected in HeLa-shRHAU cells pre-
treated with doxycycline (1 μg/ml) for 5 days. 24 h after transfection, the cell lysate and total RNA were prepared. 
(A) Western blot of total cell lysate of transfected cells. Endogenous or exogenous RHAU was detected using the 
anti-RHAU monoclonal antibody. (B) Real-time PCR using the collected RNAs (1-3) with various primer sets as 
indicated. 1: dox- with empty vector, 2: dox+ with empty vector, 3: dox+ with the expression of Flag-RHAUsm.  
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Finally, transcriptional activity was tested for RHAU candidate targets picked 
from the microarray. Nuclear run-on assay using isolated nuclei from HeLa-
shRHAU cells showed an increase in transcriptional activity of one of the 
upregulated genes (DAPK1) in RHAU knockdown cells (Figure 17). Taken 
together, these results indicate that RHAU influences gene expression at 
different steps including transcription and mRNA decay, depending on the type 
of the gene.  
 
 
 
 
 
 
 
 
Figure 17. Nuclear run-on assay using HeLa-shRHAU cells. Nuclei were isolated from doxycycline-
treated or non-treated cells, and cell-free transcription was performed as described in the Materials and 
Methods section using radio-labeled UTP. Isolated radio-labeled RNA was hybridized with the indicated 
DNA probes cross-linked on the nylon membrane. The signal intensity of each probe was normalized by 
GAPDH. 
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3.03. RHAU on stress-response.  
 
3.03.01. Influence of RHAU depletion on cell growth.  
 
We have observed mild growth retardation of RHAU knockdown cells in normal 
culture condition, although they could continue proliferation for more than two 
weeks (Figure 18A). In contrast to the normal culturing condition, RHAU 
knockdown caused severer growth defect as a result of decreased viability when 
cells were serum-starved, despite doxycycline non-treated HeLa-shRHAU cells 
and control HeLa-shLuc cells (with or without doxycycline pre-treatment) were 
able to grow in starved medium (Figure 18B, C). To support it, more numbers of 
apoptotic annexinV-positive cells were detected in RHAU knockdown cells than 
controls in starvation and when treated with other apoptosis inducer, 
staurosporine (Figure 18D). Furthermore, Western blottings detecting apoptotic 
markers such as cleaved-caspase3 and cleaved-PARP showed that RHAU 
knockdown cells underwent apoptosis significantly faster than control cells in 
starvation medium (Figure 18E). These observations suggest that RHAU have 
anti-apoptotic effect in stressed culture conditions.   
 
Figure 18. RHAU-knockdown cells undergo apoptosis upon serum-starvation. HeLa-shLuc or HeLa-shRHAU 
cells were treated or not treated with doxycycline for 5 days. Then cells were seeded in 12-well plates at 1.5×105 
cells/well (A) or 3.0×105 cells/well (B) with or without doxycycline. (A) Viable cells were counted every 24 h by 
ViCell. (B) Culture medium was replaced with serum-free medium 24 h after cell seeding. Viable cell numbers and 
viability of cells were counted every 24 h using ViCell. Error bar, SD of four replicates. (C) Phase-contrast images 
taken for 24hr-starved HeLa-shRHAU cells either cultured with or without doxycycline. (D) HeLa-shRHAU cells 
cultured with serum-free medium for indicated hours or treated with 1 μM staurosporine (STS), protein kinase 
inhibitor that induces apoptosis, for 4 hours were collected to be analyzed by FACS to detect annexinV-positive cells. 
(E) HeLa-shRHAU cells were cultured in serum-free medium for indicated hours and collected for Western blotting. 
Same amount of whole cell lysates were loaded and analyzed using the antibodies indicated.  
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3.03.02. Microarray analysis using cells under serum-starvation.  
 
We, therefore, attempted to identify target mRNAs of RHAU under stressed 
condition. HeLa-shRHAU cells were first treated with doxycycline for 5 days and 
then the medium was replaced with a serum-minus medium for 24 h prior to 
microarray analysis. In this analysis, we could first pick up as starvation-
sensitive genes which showed different expression levels in starved conditions 
compared to serum-containing conditions irrespective of doxycycline pre-
treatment (See gene lists in Appendix IV). The starvation-sensitive genes 
common in both HeLa-shLuc and HeLa-shRHAU cell line (in dox-) included the 
MAP-kinase inhibitor DUSP6 (14-fold up-regulation), the apoptosis-inducer 
TRAIL (13-fold up-regulation), and transgelin (20-fold down-regulation) which is 
involved in cytoskeleton reorganization; these may collectively contribute to the 
observed decrease in cell growth. We found that RHAU-regulated mRNAs were 
significantly enriched with these starvation-sensitive genes (Table 3B), 
indicating a close relationship between cellular responses induced by RHAU 
knockdown and serum starvation. In fact, most mRNAs that were up- or down-
regulated in RHAU knockdown in the serum-containing condition showed the 
same changes under the serum-starvation condition (Table 3C). In addition, the 
effect of RHAU knockdown during serum-starvation was more pronounced for the 
down-regulated mRNAs, suggesting that RHAU is involved in the activation of 
gene expression in serum-starved conditions. 
 
 
 
TABLE 3.  Comparison of probe sets with significantly altered steady-state levels 
in HeLa-shRHAU cells and starvation-sensitive genes.   
 
Number of common probe sets between the sets that significantly increase or decrease their expression values in 
HeLa-shRHAU cells between dox- and dox+ (defined by P<0.05 and a minimal fold change, see Materials and 
Methods) and sets defined by additional characteristics are shown. The significance of the overlap is indicated as 
n.s.; not significant, *; P<0.01, **; P<0.001, ***; P < 2e-16, calculated using the hypergeometric distribution, with 
n corresponding to the total number of genes in the column-set and N indicating the total number of genes 
analyzed in both column- and row-sets. (A) Fold difference of total mRNA amount in HeLa-shRHAU cells 
between dox- and dox+ (P<0.05). N=30,599. Up, up-regulated in dox+; down, down-regulated in dox+. (B) 
Starvation-sensitive genes. Probe sets showing more than 2-fold difference (P<0.05) in both HeLa-shLuc and 
HeLa-shRHAU cells between FCS-containing culture and serum-starved condition. N=30,599, n=593. (C) Probe 
sets showing 1.5 fold or 2-fold difference in starved HeLa-shRHAU cells between dox+ and dox-.  N=30,599, 
n1.5fold-up=153, n1.5fold-down=1,685, n2fold-up=38, n2fold-down=256. 
 
   CRHAU-KD in STV 
  
ASteady-state
 
BSTV-
sensitive >1.5 fold > two-folds 
up 428  ***45 ***75 ***25>1.5 fold down 474  ***63 ***346 ***129
up 58      **12  ***18  ***12> two-folds down 67  ***18  ***55  ***47
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Section 4  -  Discussions 
 
 
 
4.01. RHAU is a nuclear-enriched protein.  
 
Previous studies and the current 
work have shown that RHAU is 
localized predominantly in the 
nucleus, but with significant 
expression in the cytoplasm. Cell 
fractionation has also shown RHAU 
abundance in the nucleus and, 
furthermore, in the nuclear-insoluble 
fraction, suggesting that RHAU is 
tightly associated with the nuclear 
structure where it has a role. Since 
RHAU is a large nuclear protein with 
a molecular weight of 110 kDa, it is 
likely to be transported through the 
nuclear pore complex by an active 
transport mechanism requiring a 
nuclear localization signal (NLS) 
(Stewart 2007). Deletion experiments 
have shown that the N-terminal 
region of RHAU, containing a glycine-
rich motif, is required for its nuclear 
localization. In addition, an EGFP-
tagged N-terminal domain (of about 
50 kDa) resulted in perfect nuclear 
localization and higher accumulation 
than with the full-length RHAU, suggesting that this region contains the NLS. 
This was supported by observations in GST pull-down experiments where the N-
terminal domain of RHAU was co-precipitated with the general nuclear import 
factors importin-α and importin-β (Figure 21). The nuclear-cytoplasmic 
transportation of RHAU may also be regulated by an active nuclear export 
mechanism involving a putative leucine-rich nuclear export signal (NES) located 
at the end of the helicase domain (see Figure 9). We observed that RHAU and a 
cytoplasmic isoform, RHAUΔ14, that lacks 14 amino acids in the helicase domain 
but still possesses the putative NES, were totally confined to the nucleus when 
cells were treated with leptomycin B, an inhibitor of the nuclear export factor 
CRM1 (Kudo et al. 1998). This suggests that RHAU is a nuclear shuttling protein 
(Figure19). However, it is currently unclear whether RHAU is carried directly by 
CRM1 or in association with other molecules, including mRNA and mRNA-
binding proteins. It seems that RHAU tightly associates with RNA in cells: [1] In 
situ nuclear extraction experiments showed that RHAU was completely released 
from the nucleus by treatment of cells with RNase but not DNase; [2] During 
 
 
 
Figure 19. Leptomycin B inhibits nuclear export of 
RHAU and RHAU isoform.  COS7 cells were 
transfected with EGFP-RHAU or EGFP-RHAUΔ14. 
leptomycin B (10 ng/ml) or its solvent (ethanol) was 
added to the medium 8 h prior to fixation.  Cellular 
localization of EGFP-proteins was observed in greater 
than 200 cells under microscope. N: Nucleus, 
C:cytoplasm.   
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immunoprecipitation, RHAU is much more accessible to antibody in lysates 
treated with RNases than without (Figure 8A, compare lanes 2 and 3 or 5 and 6 
in IP; also observed in the previous report (Tran et al. 2004)); [3] RHAU interacts 
with various proteins including RNA-binding proteins only in the presence of 
RNA. Messenger RNAs are always associated with RNA-binding proteins from 
sites of transcription in the nucleus to the cytoplasm (Dreyfuss et al. 2002). 
Although the major mRNA export pathway in mammalian cells is that via the 
TAP/p15 complex, which is a CRM1-independent pathway, it has been reported 
that CRM1 is specifically involved in nuclear export of ARE-containing mRNAs 
(Gallouzi and Steitz 2001). It is, therefore, reasonable to assume that RHAU is 
exported as a part of RNP complexes containing AREs via CRM1. Further 
investigation is required to determine which factors and mechanisms are 
involved in the nuclear export of RHAU.  
 
The regulation of cellular traffic is important for RHAU function, since RHAU 
probably has different roles in different cellular compartments. Therefore, it is 
interesting to understand when and how its transport is regulated. To determine 
whether RHAU cellular transport is regulated in response to extracellular 
signals, we subjected cells to various stimuli. There was a significant difference 
in EGFP-RHAU localization when cells were serum starved (Figure 20) but not 
after treatment with insulin, EGF, or hydrogen peroxide (data not shown). RHAU 
tended to localize in the cytoplasm rather than the nucleus in serum-starved 
COS7 cells. Since this effect was not observed in HeLa cells, it may be cell- or 
cellular condition-specific but it is an interesting observation since we have 
shown that RHAU plays an anti-apoptotic role in cells cultured in serum-free 
medium. In this scenario, RHAU may have a cytoplasmic role, such as regulating 
mRNA decay during stress. It will be interesting to know whether RHAU 
localization varies with cell type. If the function of RHAU is correlated with its 
cellular localization, different localization patterns may be observed depending 
on cell function.  
  
 
 
 
 
 
Figure 20. Serum-starvation causes cytoplasmic 
localization of EGFP-RHAU. COS7 cells were 
transfected with EGFP-RHAU. Cells were cultured in 
serum-free medium for 24 hours prior to fixation. 
Cellular localization of EGFP-proteins was observed in 
greater than 200 cells under microscope. N: Nucleus, 
C:cytoplasm.   
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4.02. ATPase activity and localization.  
 
The regulation of the nuclear-cytoplasmic shuttling of RHAU is more complex 
than just a simple balance between nuclear import and export, since its ATPase 
activity and ongoing RNA synthesis are also involved. We observed that the 
ATPase-deficient mutant RHAU-E335A is completely excluded from the nucleus. 
Therefore, it is possible that movement of RHAU is tightly linked to its 
enzymatic activity; for example, its interactions with other proteins or RNAs 
important for nuclear import and/or export may be regulated by RHAU ATPase 
activity. The cytoplasmic localization of the RHAU mutant may be explained 
either by the acceleration of nuclear export or the inhibition of nuclear import. It 
is possible that RHAU nuclear activity depending on ATPase activity retains 
RHAU in the nucleus. However, RHAU hydrolyzes ATP more rapidly than other 
RNA helicases (Vmax: 77nmol/min/μg, Akimitsu unpublished) and, therefore, it is 
likely that the turnover of RHAU association with other proteins is also rapid if 
the interaction requires ATPase activity. RHAU ATPase activity destabilizes 
ARE-mRNA (Tran et al. 2004). Thus, if ATP-hydrolysis is required for the release 
of ARE-mRNAs from the degradation complex containing RHAU, an ATPase-
deficient RHAU mutant would be unable to dissociate from RNA, which would 
inhibit further import of the protein into the nucleus. Alternatively, RHAU may 
have different conformations depending on whether it is bound by ATP or ADP, 
thus affecting its interaction with regulatory proteins that influence RHAU 
movement across the nuclear membrane. In accordance with this, several RNA 
helicases have been reported to exhibit different conformations upon ATP and/or 
nucleic acid binding (Jankowsky and Fairman 2007).  
 
 
 
4.03. Transcriptional arrest-dependent localization of RHAU to nucleolar caps. 
 
In the nucleus, RHAU was distributed throughout the nucleoplasm but especially 
concentrated in the nuclear speckles. Nuclear speckles are irregular forms of 
subnuclear structure located in interchromatin regions of the nucleoplasm in 
mammalian cells. A speckle is a site at which actively transcribed mRNAs and 
RNA-processing factors are concentrated and, therefore, where efficient recycling 
of RNA-metabolic proteins, such as splicing factors, transcription factors, and 
nuclear export factors, is managed (Lamond and Spector 2003), (Hall et al. 2006). 
According to a proteomic analysis of biochemically isolated speckles from mouse 
liver nuclei, the components of nuclear speckles include not only splicing factors 
but also various RNA-related proteins, such as transcription factors and mRNA 
transport factors. Several DEAD/DExH RNA helicases, which might play a role 
in modifying or maintaining RNA-RNA and RNA-protein interactions in the 
speckles, were also identified (Saitoh et al. 2004). Since RHAU itself was not 
detected in this analysis and the RHAU signal in the speckles was not as 
prominent as that of SC35 in our localization study, RHAU may not be confined 
to the speckles but rather shuttles between these structures and other parts of 
the nucleus.  
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Dynamic movement of RHAU was indeed observed in transcriptionally arrested 
cells. Unexpectedly, we found that RHAU is localized in the cap-like structures 
around nucleoli in ActD-treated cells, which were located close to 
heterochromatin and contained the RNA helicases p68 and p72. The nucleolus is 
a highly dynamic organelle, disassembling and reforming during the cell cycle 
(Shaw and Jordan 1995; Raska et al. 2006). In quiescent cells or cells subjected to 
transcriptional arrest, the nucleolus segregates and a cap-like structure, the 
nucleolar cap, appears on its surface (Malatesta et al. 2000; Shav-Tal et al. 2005). 
During this event, protein and RNA components of other nuclear bodies such as 
Cajal-, SMN-, and PML bodies, as well as some nucleoplasmic RNA-binding 
proteins including the RNA helicases p68 and p72, are sorted into the nucleolar 
caps, whereas conversely some nucleolar proteins are dispersed into the 
nucleoplasm (Shav-Tal et al. 2005). Similarly, proteomic analysis has shown that 
the protein composition of isolated nucleoli alters significantly upon inhibition of 
transcription by ActD (Andersen et al. 2002; Andersen et al. 2005). This indicates 
that nucleolar components can be dynamically reorganized in response to the 
metabolic state of the cell. Transcription is the major energy-consuming process 
in the active nucleus and is functionally and physically coupled to other RNA 
metabolism steps. Thus, once transcription is arrested by ActD, this 
orchestration of the RNA metabolic process is broken down and nuclear 
morphology is significantly altered. ActD blocks RNA polymerase II complexes in 
their elongation process, by which part of the transcriptional machinery may be 
left sitting on the DNA template. On the other hand, an excessive pool of free 
post-transcriptional factors released from the transcription machinery may be 
sorted into the segregated nucleolus where pre-rRNAs accumulate, because many 
of those proteins possess RNA-binding activity. Therefore, proteins sorted to 
nucleolar caps upon transcriptional arrest are considered to be proteins 
dynamically moving in the nucleus and associated with various RNA metabolic 
processes. The RNA helicase RHAU may be one such regulatory protein shuttling 
between splicing speckles and other compartments in the nucleus, with the 
consequence that it changes its nuclear localization when transcription is 
arrested. 
 
 
 
4.04. Microarray to determine the RHAU target gene and RNA.  
 
The finding that RHAU is actively and dynamically translocated in the nucleus 
prompted an investigation of its function there. A DNA microarray approach was 
taken using the ActD-chase method to identify genes or mRNAs misregulated by 
knockdown of RHAU. Based on the data collected at five time points after the 
addition of ActD, exponential decay of mRNAs was recorded and 5,613 mRNA 
half-lives were compared in cells expressing or not expressing RHAU. Although it 
has been reported that transfection of siRNAs as well as transient expression of 
shRNA expressed from both plasmid and lentiviral DNA vectors can trigger an 
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interferon response (Bridge et al. 2003; Sledz et al. 2003), activation of PKR that 
upregulates interferon-β in response to dsRNAs (Kumar et al. 1994) was not 
detected in our system (data not shown). The expression of shLuc affected the 
expression of only two genes, which also suggests that inducible expression of 
shRNA provides little non-specific up- or downregulation of cellular transcription. 
Furthermore, changes in expression of many RHAU targets was reversed when a 
silent-mutant of RHAU was exogenously expressed, indicating that the genes 
tested were indeed targets of RHAU. Taken together, intrinsic and inducible 
expression of shRNA using stably transfected cells is an efficient tool to 
downregulate mammalian mRNAs, causing fewer side effects than other methods 
using RNA interference.  
 
 
 
4.05. RHAU changes gene expression through a mechanism not involved in 
mRNA degradation.  
 
Of the 125 gene sets showing at least a twofold change in steady-state expression 
relative to RHAU-expressing cells, only two had correlating alterations in mRNA 
half-life and steady-state level, suggesting that RHAU influence on gene 
expression is mostly not through regulation of mRNA decay. It is possible that 
RHAU is involved in transcriptional regulation in the nucleus, as transcription of 
DAPK1 was seen to be altered by RHAU knockdown in nuclear run-on assays. 
We also showed that RHAU interacts with the transcriptional regulators p68, 
p72, and HDACs, and that RHAU, p68 and p72 are closely localized in nuclear 
speckles as well as around the nucleolar caps in transcription-arrested cells. 
Since these interactions were RNA-dependent, it is likely that RHAU resides in a 
part of the large transcription-related complex including RNA. RHAU is 
concentrated in nuclear speckles in normal culture conditions, where it may 
associate with pre-mRNA, splicing factors and transcription factors. Thus, we 
also do not rule out the possibility that RHAU influences other RNA metabolic 
steps in the nucleus, such as splicing and mRNA export. Further studies are 
required to test how many RHAU-influenced genes are regulated by transcription 
or by other steps of RNA metabolism.  
 
In addition, RHAU may regulate gene expression via direct binding to DNA. One 
possibility related to the G4 resolvase activity of RHAU. Single point mutation 
analysis and compounds stabilizing the G4 structure indicate that the structure 
formed in the c-myc promoter acts as an inhibitory cis-element of its 
transcription (Siddiqui-Jain et al. 2002). At least in this example, the G4 
structure functions as a transcriptional repressing element and, thus, resolving 
this structure is expected to activate transcription. Indeed, there was a slight 
enrichment of genes containing putative G4 sequences in their promoters 
amongst the genes downregulated after RHAU knockdown, indicating that these 
genes may be activated by RHAU through its resolvase activity. However, despite 
the high frequency of genes containing putative G4 sequences (42.7% of the total 
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human genome (Huppert and Balasubramanian 2007)), so far only the c-myc 
gene has been shown experimentally to be regulated by a G4-forming sequence in 
the promoter. Thus, we need to further investigate whether the existence of the 
G4 structure in RHAU target genes in fact affects their transcription. G4-forming 
sequences are also found in telomeric repeats, which are considered important for 
the maintenance of telomeric structures and, consequently, for genome stability. 
It is unlikely, however, that RHAU is engaged in the maintenance of telomeric 
structures, since we did not observe RHAU co-localization with TRF2, a telomere-
binding protein, in the HeLa cell nucleus (Figure 21).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.06. Involvement of RHAU in mRNA degradation.  
 
In the analysis of mRNA decay rate, 99 mRNAs were significantly stabilized and 
200 mRNAs were destabilized after RHAU knockdown, although surprisingly the 
steady-state levels of the majority of these mRNAs were not significantly 
affected. A similar phenomenon was, in fact, observed in our original study of 
RHAU (Tran et al. 2004), where it was shown that overexpression of RHAU 
accelerated the decay of uPA mRNA despite the absence of changes in its steady-
state levels, suggesting that RHAU increased transcriptional activity of the same 
gene under these conditions. Since many mRNAs were not only stabilized but 
also destabilized after RHAU knockdown, including both ARE and non-ARE 
mRNAs, the effect of RHAU on mRNA decay may not necessarily be restricted to 
ARE-containing mRNAs. At the moment, however, we are unable to distinguish 
between direct and indirect targets of RHAU in this study. It is also possible that 
some of the alterations in mRNA decay were caused by changes in the expression 
 
 
 
 
Figure 21. EGFP-RHAU is not co-localized with telomeric 
structures.  HeLa cells were transfected with EGFP-RHAU. 
For ActD treatment, the drug (5 μg/ml) was added to the 
culture 2 h prior to fixation. Cells were immunostained with 
anti-TRF2 antibody (in red). The merging of two colors for 
EGFP and TRF2 is shown. Scale bar: 5 μm. 
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of other mRNAs. Thus, further approaches, such as in vitro mRNA decay assays, 
will be required to determine the direct mRNA targets of RHAU. 
 
 
 
4.07. Relationship of regulations by transcription and mRNA stability.  
 
Of the steady-state upregulated mRNAs, 78% showed no changes (Group1 in 
Figure 13) in half-life and the remaining 22% showed decreased half-lives 
(Group2), which was a statistically significant enrichment. mRNAs in Group2 
with both increased steady-state levels and shorter half-lives after RHAU 
knockdown appear contradictory but this might be explained by homeostatic 
regulation between transcription and mRNA decay. When transcription is 
activated, the stabilities of mRNAs coded by a given gene might be regulated in 
the opposite direction in preparation for imminent suppression of transcription. 
The activation of both transcription and mRNA decay at the same time is an 
energy-consuming process, but this response will ensure rapid restoration of the 
initial conditions once the signal for transcriptional activation has declined. In 
support of this hypothesis, half-life differences were observed for mRNAs whose 
steady-state levels were upregulated but not those downregulated, possibly 
because change in mRNA stability to prepare approaching upregulation of 
transcription is not necessary in the latter case. This observation implies some 
type of communication between mechanisms regulating transcription and mRNA 
degradation. RHAU may be a protein that is involved in two different regulatory 
pathways and that transfers feedback about gene expression to both mechanisms. 
It would be interesting to know at the molecular level how the two processes are 
functionally coordinated by RHAU. 
 
 
 
4.08. RHAU in tumor cell growth.  
 
RHAU knockdown in HeLa cells partially reversed the characteristics of cancer 
cells, which ceased growth in serum-starved conditions as a consequence of 
decreased viability. RHAU-expressing cells divided further for a few days under 
the same conditions. Preliminary experiments in nude mice inoculating HeLa-
shRHAU cells targeting two different sequences of RHAU mRNA showed that 
RHAU knockdown slowed the growth of HeLa cell-derived tumors, suggesting 
that RHAU has a role in tumor progression (Figure 22). Several genes encoding 
potential tumor-suppressors were indeed upregulated in RHAU knockdown cells. 
For example, in RHAU knockdown cells the steady-state levels of DAPK1 (death-
associated protein kinase1: 2.1-fold), SPRED1 (Sprouty-related protein with 
EVH-1 domain: 2.3-fold), and an MAP-kinase inhibitor, DUSP6 (dual-specificity 
phosphatase 6: 2.8-fold) were all upregulated. DAPK1 is a positive mediator of 
apoptosis (Bialik and Kimchi 2006). Cancer development and metastasis 
stemming from Lewis carcinoma cells, which do not express DAPK1, are 
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suppressed when DAPK1 expression is restored (Inbal et al. 1997). It has been 
shown also that SPRED1 inactivates the Ras-dependent MAP kinase signalling 
pathway (Wakioka et al. 2001), and that its overexpression inhibits cancer cell 
motility, leading to the suppression of metastasis (Miyoshi et al. 2004). 
Furthermore, hypermethylation in the promoter regions and, consequently, 
transcriptional suppression of DUSP6 (Jeffrey et al. 2007) has been reported in 
pancreatic cancer cells (Xu et al. 2005) and also for DAPK1 in various cancer cells 
(Tang et al. 2000; Tozawa et al. 2004; Chan et al. 2005; Kuester et al. 2007). 
According to the tumor database Oncomine 3.0 
(http://www.oncomine.org/main/index.jsp), expression of RHAU is significantly 
increased in hepatocellular carcinoma, squamous cell carcinoma, and pancreatic 
adenocarcinoma, suggesting a proto-oncogenic property of RHAU in these 
cancers. Thus, examination of the role of RHAU in tumor model systems will be 
of great interest.  
  
 
 
 
Figure 22. Knockdown of RHAU in HeLa cells retards tumor growth in nude mice. HeLa-shRHAU1 or HeLa-
shRHAU2 were subcutaneously injected into the right and left flanks of CD1 female nude mice (two million cells 
per injection). Mice were fed with or without 1mg/ml doxycycline to induce shRNA expression in the injected cells 
and tumor diameter was measured constantly to estimate tumor volume. N=6 (3 mice per condition).   
 
 
 
4.09. RHAU as a multi-functional RNA helicase.  
 
Results from the current study infer that RHAU has at least two functions in 
mammalian cells, regulating gene expression through both mRNA degradation 
and transcription (or another gene expression-regulatory pathway in the nucleus). 
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So far, several RNA helicases have been shown to be multi-functional proteins, 
many of them involved in transcriptional regulation and other RNA-metabolism 
pathways (Fuller-Pace 2006). Examples include DEAD-box proteins p68 and p72, 
which are involved in the transcription regulation of various genes as well as in 
pre-mRNA processing and in alternative splicing. It is suggested that these RNA 
helicases play different cellular roles through interactions with various proteins. 
For instance, p68 can act as both a transcription activator and a repressor 
depending on whether it binds to co-activators like p300/CBP (Rossow and 
Janknecht 2003) or co-repressors like HDAC1 (Wilson et al. 2004) in different 
cellular contexts. It is possible that RHAU fulfils different functions in a similar 
way, through different molecular associations. We found that RHAU interacts 
with p68, p72 and HDACs in a fashion dependent on RNA (Figure 8). In addition, 
GST-pull-down assays using the GST-tagged RHAU N-terminal domain has 
identified many other RNA helicases, hnRNPs and factors involved in DNA 
repair or DNA replication both in the nucleus and in cytoplasm (Figure 23). Thus, 
RHAU seems to preferentially interact with RNA-related rather than DNA-
related proteins. These results suggest that RHAU functions as part of various 
RNP complexes and is involved in different processes of RNA metabolism 
through interactions with other molecules.  
 
 
 
 
 
Figure 23. GST-RHAU Nter pull-down using HeLa nuclear and cytoplasmic extracts. Bacterial purified GST or GST-
RHAU-Nterminus (1-200aa) were incubated with HeLa nuclear extract (N), Cytoplasmic S100 extract (C), or binding buffer 
(Buf). GST proteins were collected with Glutathione sepharose, loaded in 10% SDS-PAGE and stained with Coomassie Blue. 
Proteins specifically interacting with GST-RHAU N-ter were identified by LC-MSMS. 
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Overall, the results indicate that RHAU is a protein involved in various processes 
of RNA metabolism but probably in no case as a principal factor. In mRNA 
degradation, RHAU only weakly interacts with ARE-RNA compared with other 
AUBPs and affects only limited numbers of ARE-RNA. In fact, depletion of 
RHAU had only a minor effect on the degradation of many mRNAs. In 
transcriptional regulation, it is unlikely that RHAU acts as a transcription factor 
binding directly to DNA and changing promoter activities since it seems to have a 
higher affinity for RNA than DNA. Furthermore, the threshold of impact on 
steady-state levels after depletion of RHAU was limited to about twofold in most 
genes. So, the question remains of what is the actual role of RHAU in 
mammalian cells.  
 
 
 
I view RHAU as a more general and basic factor in RNA-protein complexes. The 
basic function of RHAU could be the maintenance or rearrangement of secondary 
structures of RNA and RNA-protein complexes in a process with low specificity. 
RHAU has no RNA-binding domain apart from the NTP-binding motifs in the 
helicase core domain; thus, it is unlikely that RHAU finds its specific targets 
itself. DExH-box proteins generally do not show so much specificity for their 
substrates in duplex unwinding. Yeast DEAH-box splicing factor Prp22p unwinds 
not only RNA-RNA but also RNA-DNA duplexes of various length (Tanaka and 
Schwer 2005). Human RNA helicase A also unwinds both dsDNA and dsRNA 
(Zhang and Grosse 1994). These in vitro experiments suggest that DExH-box 
helicases recognize structures of nucleotides such as the length of single and 
double strands rather than specific sequences. Furthermore, RHAU ATP-
hydrolysis activity was activated by a wide range of polynucleotides as well as 
dsRNA, dsDNA and ssDNA ((Tran et al. 2004) and unpublished data from 
Akimitsu), suggesting that RHAU has low specificity for stimulation of enzymatic 
activity.   
 
RHAU is presumably a protein passively used by other molecules in different 
contexts, rather than having an active function by itself. It gains specificity only 
through interactions with other proteins that bind to specific RNAs. For RHAU, 
NF90 is required for the interaction with AREuPA and AREuPA is required for the 
interaction with NF90. RHAU affects the decay of AREuPA only in the context of 
these two molecules. Proportionally, only a small number of RHAU molecules (a 
few percent of total RHAU expression) are found in such a complex in whole cell 
lysates, suggesting that other populations of RHAU are involved in different 
cellular processes through interactions with different molecules. If RHAU has a 
broad capacity for molecular interactions, there must be a way to increase its 
specificity. One possibility is by cellular compartmentalization. RHAU may be  
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restricted to particular cell compartments where it selectively associates with 
other molecules. In mammalian cells, RHAU is detected both in the nucleus and 
the cytoplasm, particularly in places where RNA exists at high concentrations. 
RHAU may affect transcriptional activity of some genes only when located at 
sites enriched with other transcription-related factors with which it interacts.  
 
Thus, to further understand this molecule, more detailed information on cellular 
transportation is required. One problem in measuring RHAU activity in whole 
cell extracts is that the activity may be diluted below detection since RHAU is 
involved in many processes at the same time. Where RHAU movement can be 
restricted to one cellular compartment, its single function should be more 
prominent. The isolation of RHAU mutants with different cellular localizations 
would facilitate such an approach. It is also important to investigate interactions 
between RHAU and other molecules in situ. For this thesis, I have carried out 
immunoprecipitation experiments using whole cell lysates treated with RNases 
to examine protein-protein interactions and their RNA dependency. However, 
this approach does not necessarily reflect the in vivo situation. It lacks 
information on cellular compartments and, thus, molecular interactions occurring 
only in a specific cellular compartment would be lost in the lysates. Furthermore, 
treatment with RNases would destroy the structures of proteins associating with 
RNAs, so RHAU probably loses even direct protein-protein interactions in which 
RHAU recognizes particular protein structures. Therefore, the visualization of 
protein-protein or protein-RNA interactions in situ will be advantageous for 
understanding molecular interactions by RHAU. Fluorescence resonance energy 
transfer (FRET) using fluorescent proteins could be one method to provide such 
information. Furthermore, live-cell imaging should also provide important 
information, such as the velocity of molecular movements in different cellular 
conditions or the relationship between enzymatic activity and RHAU movement.  
 
More important, the definition of the basic functions of RHAU is necessary in 
order to fully understand this molecule. Since RHAU activity exhibits low 
specificity, it is probably difficult to determine its RNA or protein substrates in 
crude whole cell extracts. An important issue then is how RHAU affects RNA-
protein complexes, which could be answered by in vitro experiments, rather than 
to determine in which pathway RHAU is involved. Does it use the unwinding 
activity of duplex RNAs or RNPase activity to dissociate proteins from RNAs, or 
has it other as yet unknown activities? Answers to these basic questions will 
reveal the general function of RHAU and, thus, its involvement in various 
cellular processes.
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Appendix - I : Oligonucleotides used in this study 
 
 
 
 
Primers used for cDNA cloning                                  5' - 3' 
shRHAU1-s 
GATCCCGGGAACTGCGAAGAAGGTATTCAAGAGATACCTTCTTCG
CAGTTCCCTTTTTGGAAA 
shRHAU1-as 
AGCTTTTCCAAAAAGGGAACTGCGAAGAAGGTATCTCTTGAATAC
CTTCTTCGCAGTTCCCGG 
shRHAU2-s 
GATCCCGCTGTCATCTGTGCTGGTTTTCAAGAGAAACCAGCACAG
ATGACAGCTTTTTGGAAA 
shRHAU2-as 
AGCTTTTCCAAAAAGCTGTCATCTGTGCTGGTTTCTCTTGAAAAC
CAGCACAGATGACAGCGG 
RHAUsm-s GATTATGTAAGGGAACTACGGAGAAGGTATTCTGC 
RHAUsm-as GCAGAATACCTTCTCCGTAGTTCCCTTACATAATC 
E335A-s GTTAGTCATATCGTACTTGATGCAATCCATGAAAGAAATCTGCAG 
E335A-as CTGCAGATTTCTTTCATGGATTGCATCAAGTACGATATGACTAAC 
RHAU 2 fw BamHI GATTA GGATCC CATGAGTTATGACTACCATCAG 
RHAU 201 fw BamHI CG GGATCC CAGCATTTCAGAGAAAAGCTG 
RHAU 379 fw BamHI CG GGATCC GGTAACTGTCCAATGATACAT 
RHAU 483 fw BamHI CG GGATCC GTTTTGGAAGAAGAGGATGGT 
RHAU 651 fw BamHI CG GGATCC ATTGCTTATTTTCTGAGTAGA 
RHAU 200 rv EcoRI G GAATTC C CATTTCAATATACCGAAGGTC 
RHAU 378 rv EcoRI G GAATTC C AAAATATTCTGAAAACTTTTC 
RHAU 482 rv EcoRI G GAATTC C AATGTATCGGATGAGGGCAAC 
RHAU 650 rv EcoRI G GAATTC C TCCACCTAGCCTTAAAATCTT 
RHAU1008 rv EcoRI G GAATTC C GCTGTAATATCCATCCTGGAA 
Flag-s AGCTTGCCGCCATGGACTACAAGGACGACGACGACAAGG 
Flag-as GATCCCTTGTCGTCGTCGTCCTTGTAGTCCATGGCGGCA 
HA-s AGCTTGCCGCCATGGCTTACCCATACGATGTTCCAGATTACGCTG 
HA-as  GATCCAGCGTAATCTGGAACATCGTATGGGTAAGCCATGGCGGCA 
p68-fw-BamHI AT GGATCC ATGTCGGGTTATTCGAGT 
p68-rv-XhoI C CTCGAG TTATTGGGAATATCCTGTTG 
p72-fw-BamHI AT GGATCC ATGCGCGGAGGAGGCTT 
p72-rv-XhoI C CTCGAG TCATTTACGTGAAGGAGGAGGA  
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Primers used for real-time PCR     5' - 3' 
NDUFA12-fw ATGGCATCGTTGGCTTCAC 
NDUFA12-rv GCCAGTCACGTTGAATTTATGG 
MARK1-fw TGTATTCTGGAGGTAGCATGGC 
MARK1-rv CGTAAGGCTGCTGTCTTTTCC 
DUSP6-fw CTGAGGCCATTTCTTTCATAGATG 
DUSP6-rv CACAGTCACAGTGACTGAGCG 
THBS1-fw TCCGCAAAGTGACTGAAGAGA 
THBS1-rv GCAGCTATCAACAGTCCATTCC 
NTN4-fw AACTGCTCCGCTACATTTGG 
NTN4-rv TAACCTCTCCTCCAGTGCATG 
HMGA2-fw AGCAAGAACCAACCGGTGA 
HMGA2-rv TTCTCCAGTGGCTTCTGCTTTC 
CDKN1C-fw TGAGCCAAAGCCCAAAGA 
CDKN1C-rv TGCTACATGAACGGTCCCA 
CXorf12-fw CGCCAATACTGAAAAAGGCA 
CXorf12-rv ATTTCCGAGGCAGATGCTG 
TERF2-fw AAGGACCCCACAACTCAGAA 
TERF2-rv TCTGCTGGAAGGTCTCATATGA 
MCP-fw GCCCCCAATATGTGAAAAGG 
MCP-rv GAAAATGGATCTGGTCCAGG 
TMF1-fw CAAAGGATAGTGAGGCACAGG 
TMF1-rv AAGGTCCCCCACTTGAATG 
SNCA-fw ACAGTGGCTGAGAAGACCAAAG 
SNCA-rv TTGACAAAGCCAGTGGCTG 
DAPK1 QuantiTect Primer Assays (QIAGEN), Hs_DAPK1_SG_1 
 
 
 
Oligonucleotides used in this thesis are shown.  
Underline: sequence generating RHAU-specific shRNA (shRHAU1-s and –as, shRHAU2-s and -as) 
and mutation sites (RHAUsm-s and -as, E335A-s and -as). Italic: restriction sites.  
 
Primers for real-time PCR were designed using Primer ExpressTM (Applied Biosystems, version 2.0.0). 
Primers’ Tm values are set about 60 °C.  
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Appendix - II : RHAU-target mRNAs (on steady-state mRNA level) 
Probe sets showing up-regulation of steady-state mRNA in shRHAU dox+ cells.  
 
 
Up- and down-regulated probe sets in shRHAU cells or shLuc cells after doxycycline-treatment (dox+) are shown. 
ARE, clusters of ARE set in the ARED (http://rc.kfshrc.edu.sa/ARED/) are shown if gene contains an ARE 
sequence; Fold change, fold change between dox- and dox+ derived by expression value in dox+ divided by dox-; 
t1/2, half-life in each sample; SE, standard error of half-life; sig-change, whether there is a significant changes of 
half-life between dox- and dox+ (P<0.05); dec, decreased half-life in dox+, inc, increased half-life in dox+; NA, 
not available.  
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Probe sets showing down-regulation of steady-state mRNA in shRHAU dox+ cells.  
 
Probe sets showing up-regulation of steady-state mRNA in shLuc dox+ cells. 
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Appendix - III  : RHAU-target mRNAs (on mRNA stability) 
Probe sets showing significantly decreased half-life in shRHAU dox+ cells.  
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Probe sets showing significantly increased half-life in shRHAU dox+ cells. 
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Appendix - IV : Starvation-sensitive genes 
 
Probe sets showing up-regulation in starving culture condition.  
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Probe sets showing down-regulation in starving culture condition. 
 
Up- and down-regulated probe sets in both HeLa-shLuc and HeLa-shRHAU cells (dox-) in serum-starved (STV) 
condition compared to not-starved condition. fold change, between not-starved (cells cultured with FCS) and 
starved cells derived by expression value in FCS- divided by FCS+ ;SE,, standard error of the fold-differences. 
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09. 2006  EC Marie Curie scholarship for traveling grant for 
apoptosis meeting.  
 
01. 2005 to 12. 2005 Research Grant from Swiss cancer league.   
  
04. 2003 to 12. 2007 International Ph.D. Program Scholarship from  
Friedrich Miescher Institute.   
 
04. 2001 to 03. 2003  Scholarship from the Japan Scholarship Foundation.  
  
  
 
 
Research Experiences 
 
Ph.D study  04. 2003  to 12. 2007 
Biological roles of DExH RNA helicase, RHAU 
Publication 
Transcription-dependent nucleolar cap localization and possible nuclear 
function of DExH RNA helicase RHAU 
Fumiko Iwamoto, Michael Stadler, Kateřina Chalupníková, Edward 
Oakeley and Yoshikuni Nagamine, Exp.Cell.Res (submitted) 
RNA and DNA 
Northern blot, RNA degradation assay, Nuclear Run-on assay, in vitro 
ATPase assay, in vitro transcription, synthesis and transfection of 
dsRNA, siRNA, Chromatin immunoprecipitation (ChIP), cloning of cDNA, 
site-directed mutagenesis, methylation-specific PCR, DNA microarray 
(statistical analysis using Expressionist, Excel, Pathway, and R)  
Protein 
Purification of recombinant proteins (from E.Coli and insect cells), Pull 
down experiment using GST proteins, Immunoprecipitation, Western 
blot, Purification of antibodies and antigens (recombinant His-protein)  
Technical 
expertise 
Cell and Animal model 
Immunofluorescence, Confocal microscope (ZEISS LSM meta), Luciferase 
reporter assay, apoptosis assay using FACS, cell proliferation assay, 
Tumor development experiments in nude mice 
 
Bachelor and Master’s study   04. 2001  to 03. 2003 
Regulation of nuclear transport and protein degradation of PPARα and γ 
Summary  
PPARs are ligand-induced transcription factors that have important roles 
on lipid metabolism and adipocyte differentiation. I have identified 50 
amino acid-nuclear localization signals (NLS) of PPARs that were 
necessary and sufficient for their nuclear translocation. I found that 
ligands induce their nuclear translocation by live-cell imaging using 
confocal microscope. In addition to that, I discover ubiquitination of the 
NLS that were necessary for the protein degradation, thus I could show 
the important relationship between protein degradation and cellular 
compartmentalization.  
 
Technical diploma 
09.2003 Swiss animal course (module 1)  
 
Conferences attended 
 
09.2006 14th Euroconference on Apoptosis, Chia, Italy 
10.2005 Novartis – FMI joint meeting on Epigenetics, Switzerland  
07.2005 International helicase meeting: Helicases and NTP driven nucleic acid 
machines, Arolla, Switzerland    
(selected as an oral presenter) 
10.2004 Novartis Corporate Research Conference, Boston, USA  
10.2003 Novartis – FMI joint meeting on Epigenetics, Emmetten, Switzerland  
06.2003 First International meeting on ARE’s and AUBP’s in mRNA stability and 
translational control, Florence, Italy 
2003 –2007 Annual meetings of Friedrich Miescher Institute, Switzerland.   
(selected as an oral presenter, 2006)  
10.2002 75th Annual meeting of Japanese Biochemical Society, Kyoto, Japan  
12.2001 24th Annual meeting of the Molecular Biology Society of Japan, Yokohama  
12.2000 23rd Annual meeting of the Molecular Biology Society of Japan, Kobe, Japan  
 
 
 
 
  
 
